AU2017200015B2 - Efficient systemic treatment of dystrophic pathologies - Google Patents

Abstract

EFFICIENT SYSTEMIC TREATMENT OF DYSTROPHIC PATHOLOGIES 5 A composition comprising a gene therapy product for use in the treatment of a dystrophic disease in a subject, advantageously in humans, wherein: - the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin; - the composition is systemically administered.

Description

The present invention provides an efficient gene therapy product for dystrophic diseases, especially in humans and dogs, defined by the sequence encoding the microdystrophin, the delivery vehicle and the route of administration to be used.

BACKGROUND OF THE INVENTION

Duchenne muscular dystrophy (DMD) is the most frequent progressive muscle degenerative disease, affecting approximately one in 3,500 to 5000 male births. DMD is caused by deletions or mutations in the gene encoding dystrophin, located on the X chromosome. Dystrophin is required for the assembly of the dystrophinglycoprotein complex, and provides a mechanical and functional link between the cytoskeleton of the muscle fiber and the extracellular matrix. The absence of functional dystrophin causes fiber degeneration, inflammation, necrosis and replacement of muscle with scar and fat tissue, resulting in progressive muscle weakness and premature death due to respiratory and cardiac failure between the second and fourth decade of life (Moser, H., Hum Genet, 1984. 66(1): p. 17-40).

A milder form of the disease called Becker muscular dystrophy (BMD) is distinguished from DMD by delayed onset, later dependence on wheelchair support, and longer life span. BMD is caused by mutations maintaining the reading frame and the most critical parts of the gene, leading to a truncated but still functional dystrophin protein (Muntoni F et al, Lancet Neurol, 2003).

There is no cure nor effective treatment available for DMD (Rodino-Klapac, L.R. et al., Curr Neurol Neurosci Rep, 2013. 13(3): p. 332) or BMD. Conventional therapies are limited to supportive care, which partially alleviates signs and symptoms, but does not directly target the disease mechanism nor reverse the phenotype.

There currently are several therapeutic strategies being developed for DMD including in vivo gene therapy, cell transplantation therapy, pharmacologic rescue of DMD nonsense mutations and exon skipping strategies to repair the DMD gene reading frame. All of these strategies have problems to overcome, including targeting different muscle groups, optimization of delivery, long-term expression of the transgene, and potential immune response (Jamin et al., Expert Opin Biol Ther, 2014).

2017200015 03 Jan 2017

The dystrophin gene is the largest known gene in the human genome and is too large to fit inside known gene therapy vector systems. Therefore, as of today, there are essentially two gene therapy strategies for DMD with viral vectors: i) constitutive expression of antisense oligonucleotides to promote exon skipping, which is amenable to certain mutations only, and (ii) constitutive expression of a cDNA coding for a functional, reduced-size dystrophin protein (“microdystrophin” also known as “minidystrophin”).

Both strategies, use of small antisense sequences or use of microdystrophin, address the major hurdle for the use of AAV vectors in DMD gene therapy, which is their packaging capacity. AAV vectors can accommodate about 4.7 kb while the size of the wild type dystrophin cDNA is about 14 kb. To overcome this issue, a number of studies have developed partially deleted but highly functional dystrophin genes, which can be successfully packaged inside AAV vectors and were shown to improve, though not completely normalize, the dystrophic phenotype in animal models.

The mdx mouse model is commonly used to test new constructs encoding microdystrophins. However, this model has drawbacks because the mdx mouse displays a less severe form of the disease, without immune reactions. The other animal model is the

GRMD dog, which is considered more reliable to predict the therapeutic potential of a gene therapy product in humans (Kornegay etal., Mamm Genome, 2012).

Among all the proposed microdystrophin sequences, Foster H. et al. (Mol Ther, 2008. 16(11): p. 1825-32) compared in mice two different configurations of microdystrophin genes, DAB/R3-R18/DCT and DR4-R23/DCT, under the control of a muscle-specific promoter (Spc5-12) in a recombinant AAV vector (rAAV2/8). It was reported that codon human optimization of microdystrophin improved gene transfer and muscle functions in the mdx mouse model. Intravenous injection of 3.10¹¹ vg total of rAAV/8 allowed efficient cardiac gene transfer and marked dystrophin expression in the skeletal muscle and within the diaphragm.

In relation with CXMDj dogs, Ohshima S. et al. (Mol Ther, 2009. 17(1): p. 73-80) reported the administration into dogs of a rAAV8 encoding a M3 microdystrophin under the control of the CMV promoter by limb perfusion, i.e. intravenous injection under pressure.

2017200015 03 Jan 2017

Zhang Y. et al. (Hum Mol Genet, 2013. 22(18): p. 3720-29) studied the systemic (5.10¹² vg total) dual AAV9 gene therapy in DMD mice. By homologous recombination, the dual AAV vectors injected via the tail vain reconstituted a nNOS binding microdystrophin containing dystrophin repeats R16 and R17.

Similarly, Odom G. et al. (Mol Ther, 2011. 19(1): p. 36-45) demonstrated reconstitution of an expression cassette encoding a DH2-R19 mini dystrophin in mice following intravascular co-delivery of two rAAV6 vectors (2.10¹² vg total) sharing a central homologous recombinogenic region.

Wang B. et al. (J Orthop Res. 2009; 27(4): p 421-6) disclosed the intraperitoneal (i.p.) injection of 3.10ⁿvg total rAAVl vectors in neonatal mice (dKO and mdx). These AAV vectors encode the microdystrophin D3990 placed under the control of the MCK or CMV promoter.

Koppanati et al. (Gene therapy. 2010; 17(11): p 1355-62) reported in utero gene transfer in the mdx mouse via the intraperitoneal (i.p.) injection of 6.4.10ⁿvg total rAAV8 vector encoding a canine microdystrophin placed under the control of the CMV promoter.

Schinkel et al. (Human Gene therapy. 2012; 23(6): p 566-75) reported cardiac gene therapy in the mdx mouse via the intravenous (IV) injection of 10¹²vg total rAAV9 vector encoding a microdystrophin placed under the control of the CMV promoter or the cardiac-specific MLC0.26 promoter.

Gregorevic et al. (Mol. Therapy 2008; 16(4): p 657-64) reported muscular gene therapy in the mdx mouse via the intravenous (IV) injection of 10¹³vg total rAAV6 vector encoding the DR4-R23/DCT microdystrophin placed under the control of the CMV promoter.

Shin et al. (Gene Therapy 2011; 18(9): p 910-19) reported cardiac gene therapy in the mdx mouse via the intravenous (IV) injection of 3.10¹²vg total rAAV9 vector encoding a microdystrophin (hDCS2) placed under the control of the CMV promoter.

Shin et al. (J. of Gene Medicine 2008; 10(4): p 449) compared the delivery efficiency in mice of rAAV8 encoding the DCS2 microdystrophin placed under the control of the

CMV promoter, by subcutaneous injection or intravenous injection.

2017200015 03 Jan 2017

Colgan et al. (Mol. Therapy 2014; 22(S1): p S197) reported the microdystrophin and follistatin combinatorial gene delivery by intravenous injection of rAAV6 vectors in dKO mice.

In the context of DMD, a valuable therapeutic solution would be a gene therapy product having the following characteristics:

- A product which can be systemically administered, at a reasonable dose (i.e. a proper gene transfer in the target tissues) and possibly by a unique injection;

- A product which is has acceptable toxicity at that dose, and especially does not induce an adverse immune response against the dystrophin protein;

- A product having a satisfying tropism, i.e. a wide spread gene transfer on large territories of skeletal muscles, but also diaphragm and myocardium;

- A product able to ameliorate the dystrophic disease in humans.

In practice, previous reports have revealed that it is a very challenging task and several attempts have failed:

Studies using AAV2/6 vectors encoding a human-specific, but not codon-optimized, microdystrophin (DR4-R23/DCT) under a CMV promoter resulted in the limited expression and eventual destruction of injected CXMDj dog muscle fibers via the immune system at 6 weeks after discontinuation of immunosuppression, 22 weeks after initial intramuscular injection (Wang, Z. etal., Mol Ther, 2007. 15: p. 1160-66).

Clinical trials based on the intramuscular injection of AAV2/5 vectors encoding a human-specific, but not codon-optimized, microdystrophin (DR3-R21/DCT) under a CMV promoter resulted in very limited transgene expression and in an inappropriate immune response (Mendell, JR et al., N Engl J Med, 2010.363(15): p. 1429-37; Bowles, DE. etal., Mol Ther, 2012. 20(2): p. 443-55).

Therefore, there is a need in the art for an efficient treatment of dystrophic pathologies in humans, including systemic benefits in terms of survival, overall clinical score, digestive, cardiac and/or respiratory function.

2017200015 03 Apr 2018

BRIEF SUMMARY OF THE INVENTION

The present invention aims at alleviating or curing the devastating Duchenne muscular dystrophy (DMD) and/or Becker muscular dystrophy (BMD) by expressing a shorter but functional dystrophin polypeptide called microdystrophin.

For the first time, the present invention offers a promising gene therapy product, a sequence optimized microdystrophin, encapsidated in the AAV8 capsid, for treating dystrophic diseases. After systemic intravenous administration of a single dose, not only is the microdystrophin highly expressed in multiple muscles but it also results in muscle pathology improvement and improved clinical outcome measures.

Indeed, so good results obtained in a dog model, in terms of muscular, digestive, respiratory and cardiac rescue, correlated with a prolonged life in good condition, have never been reported so far in relation with this kind of pathology.

Definitions

The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

“About” or “approximately” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.

Ranges: throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that

2017200015 03 Jan 2017 range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.

“Isolated” means altered or removed from the natural state. For example, a nucleic acid or a peptide naturally present in a living animal is not “isolated,” but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is “isolated.” An isolated nucleic acid or protein can exist in substantially purified form, or can exist in a non-native environment such as, for example, a host cell.

In the context of the present invention, the following abbreviations for the commonly occurring nucleic acid bases are used. “A” refers to adenosine, “C” refers to cytosine, “G” refers to guanosine, “T” refers to thymidine, and “U” refers to uridine.

Unless otherwise specified, a “nucleotide sequence encoding an amino acid sequence” includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. The phrase nucleotide sequence that encodes a protein or a RNA or a cDNA may also include introns to the extent that the nucleotide sequence encoding the protein may in some version contain an intron(s).

“Encoding” refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (i.e., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus, a gene encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA.

The term “polynucleotide” as used herein is defined as a chain of nucleotides. Furthermore, nucleic acids are polymers of nucleotides. Thus, nucleic acids and polynucleotides as used herein are interchangeable. One skilled in the art has the general knowledge that nucleic acids are polynucleotides, which can be hydrolyzed into the monomeric “nucleotides.” The monomeric nucleotides can be hydrolyzed into nucleosides. As used herein polynucleotides include, but are not limited to, all nucleic acid sequences which are obtained by any means available in the art, including, without limitation,

2017200015 03 Jan 2017 recombinant means, i.e., the cloning of nucleic acid sequences from a recombinant library or a cell genome, using ordinary cloning technology and PCR and the like, and by synthetic means.

As used herein, the terms “peptide,” “polypeptide,” and “protein” are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a protein’s or peptide’s sequence. Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. “Polypeptides” include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. The polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof.

“Identical” refers to the sequence similarity or sequence identity between two polypeptides or between two nucleic acid molecules. When a position in both of the two compared sequences is occupied by the same base or amino acid monomer subunit, e.g., if a position in each of two DNA molecules is occupied by adenine, then the molecules are homologous or identical at that position. The percent of homology/identity between two sequences is a function of the number of matching positions shared by the two sequences divided by the number of positions compared X 100. For example, if 6 of 10 of the positions in two sequences are matched then the two sequences are 60% identical. Generally, a comparison is made when two sequences are aligned to give maximum homology/identity.

A “vector” is a composition of matter which comprises an isolated nucleic acid and which can be used to deliver the isolated nucleic acid to the interior of a cell. Numerous vectors are known in the art including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term “vector” includes an autonomously replicating plasmid or a virus. The term should also be construed to include non-plasmid and non-viral compounds which facilitate transfer of nucleic acid into cells, such as, for example, polylysine compounds, liposomes, and the

2017200015 03 Jan 2017 like. Examples of viral vectors include, but are not limited to, adenoviral vectors, adenoassociated virus vectors, retroviral vectors, and the like.

“Expression vector” refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operatively linked to a nucleotide sequence to be expressed. An expression vector comprises sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system. Expression vectors include all those known in the art, such as cosmids, plasmids (e.g., naked or contained in liposomes) and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate the recombinant polynucleotide.

The term “promoter” as used herein is defined as a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a polynucleotide sequence.

As used herein, the term “promoter/regulatory sequence” means a nucleic acid sequence, which is required for expression of a gene product operably linked to the promoter/regulatory sequence. In some instances, this sequence may be the core promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements, which are required for expression of the gene product. The promoter/regulatory sequence may, for example, be one, which expresses the gene product in a tissue specific manner.

A “constitutive” promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a cell under most or all physiological conditions of the cell.

An “inducible” promoter is a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a cell substantially only when an inducer which corresponds to the promoter is present in the cell.

A “tissue-specific” promoter is a nucleotide sequence which, when operably linked with a polynucleotide encodes or specified by a gene, causes the gene product to be produced in a cell preferentially if the cell is a cell of the tissue type corresponding to the promoter.

2017200015 03 Jan 2017

The term “abnormal” when used in the context of organisms, tissues, cells or components thereof, refers to those organisms, tissues, cells or components thereof that differ in at least one observable or detectable characteristic (e.g., age, treatment, time of day, etc.) from those organisms, tissues, cells or components thereof that display the “normal” (expected) respective characteristic. Characteristics, which are normal or expected for one cell or tissue type, might be abnormal for a different cell or tissue type.

The terms “patient,” “subject,” “individual,” and the like are used interchangeably herein, and refer to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein. In certain non-limiting embodiments, the patient, subject or individual is a human.

A “disease” is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal’s health continues to deteriorate. In contrast, a “disorder” in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal’s state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal’s state of health.

A disease or disorder is “alleviated” or “ameliorated” if the severity of a symptom of the disease or disorder, the frequency with which such a symptom is experienced by a patient, or both, is reduced. This also includes halting progression of the disease or disorder. A disease or disorder is “cured” if the severity of a symptom of the disease or disorder, the frequency with which such a symptom is experienced by a patient, or both, is eliminated.

A “therapeutic” treatment is a treatment administered to a subject who exhibits signs of pathology, for the purpose of diminishing or eliminating those signs.

As used herein, “treating a disease or disorder” means reducing the frequency or severity of at least one sign or symptom of a disease or disorder experienced by a subject. Disease and disorder are used interchangeably herein in the context of treatment.

An “effective amount” of a compound is that amount of compound which is sufficient to provide a beneficial effect to the subject to which the compound is administered. The phrase “therapeutically effective amount”, as used herein, refers to an amount that is sufficient or effective to prevent or treat (delay or prevent the onset of, prevent the progression of, inhibit, decrease or reverse) a disease or condition, including alleviating

2017200015 03 Apr 2018 symptoms of such diseases. An “effective amount” of a delivery vehicle is that amount sufficient to effectively bind or deliver a compound.

DETAILED DESCRIPTION OF THE INVENTION

In one embodiment, the present invention relates to a composition comprising a gene therapy product for use in the treatment of a dystrophic disease selected from Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) in a subject, wherein:

- the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin;

- the composition is systemically administered.

In other words, the present invention provides a method for treating a dystrophic disease in a subject, comprising systemically administrating to the subject a composition comprising a nucleic acid sequence encoding a functional microdystrophin.

In one embodiment, the present invention provides a method for treating a dystrophic disease in a subject, comprising systemically administrating to the subject a gene therapy product comprising a nucleic acid sequence encoding a functional microdystrophin. The invention concerns the use of a gene therapy product comprising a nucleic acid sequence encoding a functional microdystrophin for the preparation of a medicament for the treatment of dystrophic diseases, wherein the medicament is systemically administered.

According to a first aspect, the present invention relates to a gene therapy product for use in the treatment of a dystrophic disease in a subject.

Typically, a gene therapy product is made of 2 components:

- The encapsidated recombinant nucleic acid sequence which defines the expression cassette that provides the therapeutic benefit(s) once expressed in the target cell/tissue; and

- The viral capsid which allows proper gene transfer and to a certain extent, tissue tropism.

According to one aspect, the gene therapy product comprises a nucleic acid sequence encoding a functional microdystrophin.

2017200015 03 Jan 2017

In the frame of the invention, microdystrophin means a peptide or protein, which is shorter than the native or wild type dystrophin. In the context of the invention, the terms “microdystrophin” and “minidystrophin” have the same meaning. In the rest of the application, the term “microdystrophin” will be used, as well as the abbreviations “MD” or “pDys”.

A “functional” microdystrophin means that the corresponding peptide or protein is able to perform at least some of the functions of the wild-type dystrophin protein and is able to alleviate, at least partially, one or more of the symptoms associated with the absence of a native dystrophin, especially fiber degeneration, inflammation, necrosis, replacement of muscle with scar and fat tissue, muscle weakness, digestive, respiratory and cardiac failure, as well as premature death.

The structure of dystrophin is well documented (see Figure 1) and active fragments thereof have been disclosed (Athanasopoulos et al., Gene Ther 2004 Suppl TS109-21). As would be understood in the art, an active fragment is a portion or portions of a full length sequence that retain the biological function of the full length sequence.

The full-length dystrophin is characterized by different domains:

- A N-terminal domain which binds to actin;

- 4 hinge domains (Hl to H4);

- 24 spectrin-like repeats or rod domains (1 to 24);

- A cysteine-rich domain;

- A C-terminal domain.

According to one embodiment, the microdystrophin has at least one domain lacking, advantageously at least one spectrin-like-repeat.

According to a particular embodiment, the microdystrophin has the configuration DR430 R23/DCT, comprising 4 spectrin-like repeats, i.e. spectrin-like repeats 1, 2, 3 and 24 as shown on figure 1. More precisely, this sequence comprises deletions of rod domains 423 and exons 71-78 of the CT domain of dystrophin, and contains the last three amino acids of exon 79 of dystrophin followed by three stop codons.

Such a microdystrophin noted DR4-R23/DCT or MD1 has e.g. the amino acid sequence shown in SEQ ID NO: 3, 4 or 7.

2017200015 03 Jan 2017

In one embodiment, the nucleic acid sequence encoding the functional microdystrophin, also named ORF for “open reading frame”, is a cDNA. However, e.g. single- or doublestranded DNA or RNA can be used.

In a specific embodiment, the present invention provides compositions comprising nucleic acid sequences that are shorter than the wild-type dystrophin cDNA.

When used in the context of AAV vectors, which can accommodate about 4.7 kb, the nucleic acid sequence encoding the functional microdystrophin, as well as all the sequences required for its proper expression, should not exceed this packaging capacity. In one embodiment, the nucleic acid sequence encoding the functional microdystrophin does not exceed 4500, 4000 bp, preferably 3900, 3800, 3700, 3600 or even 3500 bp.

The nucleic acid sequence encoding the functional microdystrophin is advantageously of human origin but can also be a non-human primate, a canine, a rat or a murine sequence. In one embodiment, the nucleic acid sequence originates from the organism it will be administered to (e.g. a human sequence in humans).

According to another embodiment, the nucleic acid sequence encoding said microdystrophin is optimized for use in a given subject, advantageously in humans. Preferably, this optimized sequence is modified as follows:

- The sequence is modified to include a consensus Kozak sequence before AUG start codon within mRNA, to improve initiation of translation.

- The sequence is optimized based on transfer RNA frequencies in human and GC content is increased to promote RNA stability. As a result and in a specific case, codon optimization for humans advantageously leads to 63% of codons being modified and the GC content increased to over 60%. This of course depends on the original (before optimization) microdystrophin sequence and the target host.

According to one embodiment, the nucleic acid sequence encoding a functional microdystrophin corresponds to:

- nucleotides 586 to 4185 of sequence SEQ ID NO: 1 as shown in SEQ ID NO: 5; or

- nucleotides 586 to 4188 of sequence SEQ ID NO: 2 as shown in SEQ ID NO: 6.

2017200015 03 Jan 2017

According to one embodiment, said sequence can be an isolated nucleic acid encoding a microdystrophin having substantial homology or identity (60%, 70%, 80%, 90% 95% or even 99%) to the peptides disclosed herein, especially of sequence SEQ ID NO: 3, SEQ ID NO: 4, or even SEQ ID NO: 7.

Preferably, the nucleotide sequence of an isolated nucleic acid encoding a peptide of the invention is “substantially homologous/identical”, that is, is about 60% homologous, more preferably about 70% homologous, even more preferably about 80% homologous, more preferably about 90% homologous, even more preferably, about 95% homologous, and even more preferably about 97%, 98% or even 99% homologous to a nucleotide sequence of an isolated nucleic acid encoding the functional microdystrophin, especially of sequence SEQ ID NO:5, SEQ ID NO: 6 or even SEQ ID NO: 8.

According to another aspect, the nucleotide sequence harbored by an expression vector according to the invention is “substantially homologous/identical”, that is, is about 60% homologous, more preferably about 70% homologous, even more preferably about 80% homologous, even more preferably about 90% homologous, even more preferably about 95% homologous, and even more preferably about 97%, 98% or even 99% homologous to the sequence SEQ ID NO: 1 or SEQ ID NO: 2.

In another embodiment, the composition comprises a plasmid or a vector. According to a specific embodiment, the isolated nucleic acid is inserted into the vector. In brief summary, the expression of natural or synthetic nucleic acids is typically achieved by operably linking a nucleic acid or portions thereof to a promoter, and incorporating the construct into an expression vector. The vectors to be used are suitable for replication and, optionally, integration in eukaryotic cells. Typical vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the desired nucleic acid sequence.

In one embodiment, the composition comprises an expression vector, advantageously a viral vector. Of particular interest are the expression vectors which packaging capacity does not allow accommodation of the (wild type) dystrophin gene, including the (wild type) dystrophin cDNA.

In one embodiment, the viral vector is selected from the group consisting of a baculoviral vector, herpes viral vector, lentiviral vector, retroviral vector, adenoviral vector, and adeno-associated viral (AAV) vector.

2017200015 03 Jan 2017

According to a specific embodiment of the invention, the viral vector containing the expression construct is an adeno-associated viral (AAV) vector.

Adeno-associated viral (AAV) vectors have become powerful gene delivery tools for the treatment of various disorders. AAV vectors possess a number of features that render them ideally suited for gene therapy, including a lack of pathogenicity, moderate immunogenicity, and the ability to transduce post-mitotic cells and tissues in a stable and efficient manner. Expression of a particular gene contained within an AAV vector can be specifically targeted to one or more types of cells by choosing the appropriate combination of AAV serotype, promoter, and delivery method.

In one embodiment, the encoding sequence is contained within an AAV vector. More than 100 naturally occurring serotypes of AAV are known. Many natural variants in the AAV capsid exist, allowing identification and use of an AAV with properties specifically suited for dystrophic pathologies. AAV viruses may be engineered using conventional molecular biology techniques, making it possible to optimize these particles for cell specific delivery of nucleic acid sequences, for minimizing immunogenicity, for tuning stability and particle lifetime, for efficient degradation, for accurate delivery to the nucleus.

As mentioned above, the use of AAV vectors is a common mode of exogenous delivery of DNA as it is relatively non-toxic, provides efficient gene transfer, and can be easily optimized for specific purposes. Among the serotypes of AAVs isolated from human or non-human primates (NHP) and well characterized, human serotype 2 is the first AAV that was developed as a gene transfer vector. Other currently used AAV serotypes include AAV1, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11 and AAV12. In addition, non-natural engineered variants and chimeric AAV can also be useful.

Desirable AAV fragments for assembly into vectors include the cap proteins, including the vpl, vp2, vp3 and hypervariable regions, the rep proteins, including rep 78, rep 68, rep 52, and rep 40, and the sequences encoding these proteins. These fragments may be readily utilized in a variety of vector systems and host cells.

2017200015 03 Jan 2017

Such fragments may be used alone, in combination with other AAV serotype sequences or fragments, or in combination with elements from other AAV or non-AAV viral sequences. As used herein, artificial AAV serotypes include, without limitation, AAV with a non-naturally occurring capsid protein. Such an artificial capsid may be generated by any suitable technique, using a selected AAV sequence (e.g., a fragment of a vpl capsid protein) in combination with heterologous sequences which may be obtained from a different selected AAV serotype, non-contiguous portions of the same AAV serotype, from a non-AAV viral source, or from a non-viral source. An artificial AAV serotype may be, without limitation, a chimeric AAV capsid, a recombinant AAV capsid, or a humanized AAV capsid. Thus exemplary AAVs, or artificial AAVs, include AAV2/8 (US 7,282,199), AAV2/5 (available from the National Institutes of Health), AAV2/9 (W02005/033321), AAV2/6 (US 6,156,303), and AAVrh8 (W02003/042397), among others. In one embodiment, the vectors useful in the compositions and methods described herein contain, at a minimum, sequences encoding a selected AAV serotype capsid, e.g., an AAV8 capsid, or a fragment thereof. In another embodiment, useful vectors contain, at a minimum, sequences encoding a selected AAV serotype rep protein, e.g., AAV8 rep protein, or a fragment thereof. Optionally, such vectors may contain both AAV cap and rep proteins. In vectors in which both AAV rep and cap are provided, the AAV rep and AAV cap sequences can both be of one serotype origin, e.g., all AAV8 origin. Alternatively, vectors may be used in which the rep sequences are from an AAV serotype, which differs from that which is providing the cap sequences. In one embodiment, the rep and cap sequences are expressed from separate sources (e.g., separate vectors, or a host cell and a vector). In another embodiment, these rep sequences are fused in frame to cap sequences of a different AAV serotype to form a chimeric AAV vector, such as AAV2/8 (US 7,282,199).

According to one embodiment, the composition comprises an AAV of serotype 2, 5, 8 or 9. Advantageously, the claimed vector is an AAV8 or AAV9 vector, especially an AAV2/8 or AAV2/9 vector. More advantageously, the claimed vector is an AAV8 vector or an AAV2/8 vector.

In the AAV vectors used in the present invention, the AAV genome may be either a single stranded (ss) nucleic acid or a double stranded (ds) / self complementary (sc) nucleic acid molecule.

2017200015 03 Jan 2017

Advantageously, the nucleic acid sequence encoding the functional microdystrophin is inserted between the ITR (« Inverted Terminal Repeat») sequences of the AAV vector. Typical ITR sequences correspond to:

- nucleotides 1 to 128 of sequence SEQ ID NO: 1 or of sequence SEQ ID NO: 2 (5’ITR sequences);

- nucleotides 4511 to 4640 of sequence SEQ ID NO: 1 or nucleotides 4514 to 4643 of sequence SEQ ID NO: 2 (3’ITR sequences).

Recombinant viral particles can be obtained by any method known to the one skilled in the art, e.g. by co-transfection of 293 HEK cells, by the herpes simplex virus system and by the baculovirus system. The vector titers are usually expressed as viral genomes per mL (vg/mL).

In one embodiment, the expression vector comprises regulatory sequences, especially a promoter sequence. Such promoters can be natural or synthetic (artificial) promoters, inducible or constitutive.

In one embodiment, the promoter is an ubiquitous promoter or having a low tissuespecificity. As an example, the expression vector can harbor the phosphoglycerate kinase

1 (PGK), EF1, β-actin, CMV promoter.

In a preferred embodiment, the promoter sequence is chosen in order to adequately govern the expression of the nucleic acid sequence placed under its control, in terms of expression level, but also of tissue specificity. In one embodiment, the expression vector comprises a muscle specific promoter. Such a promoter allows a robust expression in the skeletal muscles, and possibly in the cardiac muscle as well as in the diaphragm. Examples of suitable promoters known by the skilled person are e.g. the desmin promoter, the muscle creatine kinase (MCK) promoter, the CK6 promoter, and the Syn promoter. Another promoter is the synthetic promoter C5-12 (spC5-12) as shown in sequences SEQ ID NO: 1 or 2 (nucleotides 215 to 537), which allows a robust expression in skeletal and cardiac muscles.

2017200015 03 Jan 2017

A non-exhaustive list of other possible regulatory sequences is:

- a polyadenylation signal, e.g. the polyA of the gene of interest, the polyA of SV40 or of beta hemoglobin (HBB2), advantageously in 3’ of the sequence encoding the functional microdystrophin ; The poly A of SV40 is disclosed in sequences SEQ

ID NO: 1 (nucleotides 4223 to 4353) and SEQ ID NO: 2 (nucleotides 4226 to

4356);

- sequences for transcript stabilization, e.g. intron 1 of hemoglobin (HBB2);

- enhancer sequences ;

- miRNA target sequences, which can inhibit the expression of the sequence encoding the functional dystrophin in non target tissues, in which said expression is not desired, for example where it can be toxic. Preferably, the corresponding miRNA is not present in the skeletal muscles, and possibly not in the diaphragm nor in the heart.

According to one embodiment, the gene therapy product comprises an expression vector, advantageously an AAV vector harboring the sequence SEQ ID NO: 1 or SEQ ID NO: 2, advantageously SEQ ID NO: 1. As mentioned above, the invention also encompasses “substantially homologous” sequences, that is, displaying about 60% homology, more preferably about 70% homology, even more preferably about 80% homology, more preferably about 90% homology, even more preferably about 95% homology, and even more preferably about 97%, 98% or even 99% homology to the sequence SEQ ID NO: 1 or 2.

According to the present invention, the composition comprises at least said gene therapy product, and possibly other active molecules (other gene therapy products, chemical molecules, peptides, proteins...), dedicated to the treatment of the same disease or another disease.

According to a specific embodiment, said composition does not comprise any immunosuppressive agent.

The present invention then provides pharmaceutical compositions comprising a nucleic acid of the invention, or the vector of the invention. Such compositions comprise a therapeutically effective amount of the therapeutic (the nucleic acid or vector of the invention), and a pharmaceutically acceptable carrier. In a specific embodiment, the term pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. or European Pharmacopeia or other generally

2017200015 03 Jan 2017 recognized pharmacopeia for use in animals, and humans. The term carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like.

The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsions, sustained-release formulations and the like. Examples of suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences by E. W. Martin. Such compositions will contain a therapeutically effective amount of the therapeutic, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the subject.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lidocaine to release pain at the site of the injection.

In one embodiment, the composition according to the invention is suitable for administration in humans. The composition is preferably in a liquid form, advantageously a saline composition, more advantageously a phosphate buffered saline (PBS) composition or a Ringer-Lactate solution.

The amount of the therapeutic (i.e. a nucleic acid or a vector) of the invention which will be effective in the treatment of dystrophic diseases can be determined by standard clinical techniques. In addition, in vivo and/or in vitro assays may optionally be employed to help predict optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, the weight and the

2017200015 03 Jan 2017 seriousness of the disease, and should be decided according to the judgment of the practitioner and each patient's circumstances.

Suitable administration should allow the delivery of a therapeutically effective amount of the gene therapy product to the target tissues, especially skeletal muscles and possibly smooth muscles (e.g. esophagus), diaphragm and heart. In the context of the invention, when the gene therapy product is a viral vector comprising a nucleic acid sequence encoding a functional microdystrophin, the therapeutic dose is defined as the quantity of viral particles (vg for viral genomes) containing the microdystrophin sequence, administered per kilogram (kg) of the subject.

Available routes of administration are topical (local), enteral (system-wide effect, but delivered through the gastrointestinal (Gl) tract), or parenteral (systemic action, but delivered by routes other than the Gl tract). The preferred route of administration of the compositions disclosed herein is parenteral which includes intramuscular administration (i.e. into the muscle) and systemic administration (i.e. into the circulating system). In this context, the term “injection” (or “perfusion” or “infusion”) encompasses intravascular, in particular intravenous (IV), and intramuscular (IM) administration. Injections are usually performed using syringes or catheters.

In one embodiment, systemic delivery of the composition comprises administering the composition near a local treatment site, i.e. in a vein or artery nearby a weakened muscle. In certain embodiments, the invention comprises the local delivery of the composition, which produces systemic effects. This route of administration, usually called “regional (loco-regional) infusion”, “administration by isolated limb perfusion” or “high-pressure transvenous limb perfusion” has been successfully used as a gene delivery method in muscular dystrophy (Zheng Fan et al. (2012, Molecular Therapy 20(2), 456-461).

According to one aspect, the composition is administered to an isolated limb (loco30 regional) by infusion or perfusion. In other words, the invention comprises the regional delivery of the composition in a leg and/or arm by an intravascular route of administration, i.e. a vein (transveneous) or an artery, under pressure. This is usually achieved by using a tourniquet to temporarily arrest blood circulation while allowing a regional diffusion of the infused product, as e.g. disclosed by Toromanoff et al. (2008,

Molecular Therapy 16(7):1291-99), Arruda et al. (2010, Blood 115(23):4678-88) and Fan et al. (2012, Molecular Therapy 20(2), 456-461).

2017200015 03 Jan 2017

In one embodiment, the composition is injected in a limb of the subject. In one embodiment, the subject is a mammal, preferably a human, a dog or a nonhuman primate.

When the subject is a human, the limb can be the arm or the leg. According to one embodiment, the composition is administered in the lower part of the body of the subject,

e.g. below the knee, or in the upper part of the body of the subject, e.g., below the elbow.

In one embodiment, the composition is administered to a peripheral vein, e.g. the cephalic vein. The volume of the composition to be infused can be in a range that varies between about 5 and 40% of the limb volume. The typical dose can vary between 5 and 30 ml/kg of body weight. In one embodiment, the pressure to be applied (tourniquet pressure or maximum line pressure) is below 100 000 Pa, advantageously below 50 000 Pa. In a preferred embodiment, the pressure applied is around 300 torr (40 000 Pa).

In one embodiment, the blood circulation of the limb is stopped using a tourniquet that is tightened for several minutes to more than one hour, typically between about 1 and 80 minutes, for example about 30 minutes. In a preferred embodiment, the tourniquet was applied before, during and after the administration, for example about 10 minutes prior to, about 20 minutes during and about 15 min after the infusion. More generally, the pressure is applied for several minutes, typically between about 1 and 80 minutes, for example about 30 minutes. In a preferred embodiment, the pressure is applied before, during and after the administration, for example about 10 minutes prior to, about 20 minutes during and about 15 minutes after the infusion.

In one embodiment, the average flow rate is comprised between 5 and 150 ml/min, advantageously between 5 and 80 ml/min, for example 10 ml/min. Of course, the flow rate also determines the time period during which the blood circulation is stopped and the pressure applied.

In the context of a loco-regional administration, the dose injected may vary between 10¹² and 10¹⁴ vg/kg of the patient body, preferably between 10¹² and 10¹³ vg/kg.

A preferred method of administration according to the invention is systemic administration. Systemic injection opens the way to an injection of the whole body, in order to reach the entire muscles of the body of the subject including the heart and the diaphragm and then a real treatment of these systemic and still incurable diseases. In certain embodiments, systemic delivery comprises delivery of the composition to the subject such that composition is accessible throughout the body of the subject.

2017200015 03 Jan 2017

According to a preferred embodiment, systemic administration occurs via injection of the composition in a blood vessel, i.e. intravascular (intravenous or intra-arterial) administration. According to one embodiment, the composition is administered by intravenous injection, through a peripheral vein.

The systemic administration is typically performed in the following conditions:

- a flow rate of between 1 to 10 mL/min, advantageously between 1 to 5 mL/min, e.g. 3 mL/min;

- the total injected volume can vary between 1 and 20 mL, preferably 5 mL of vector preparation per kg of the subject. The injected volume should not represent more than 10% of total blood volume, preferably around 6%.

When systemically delivered, the composition is preferably administered with a dose less than or equal to 10¹⁵ vg/kg or even 10¹⁴ vg/kg, advantageously between 10¹² vg/kg and 10¹⁴ vg/kg, more advantageously between 5.10¹² vg/kg and 10¹⁴ vg/kg, e.g. 1, 2, 3, 4, 5, 6, 7, 8 or 9.10¹³ vg/kg. A lower dose of e.g. 1, 2, 3, 4, 5, 6, 7, 8 or 9.10¹² vg/kg can also be contemplated in order to avoid potential toxicity and /or immune reactions. As known by the skilled person, a dose as low as possible given a satisfying result in term of efficiency is preferred.

In a specific embodiment, the treatment comprises a single administration of the composition.

As it will be illustrated in the examples below, the administration of the gene therapy product according to the invention is not believed to be associated with adverse immune reactions. Therefore, and according to one embodiment, said administration is not combined with any further or extra immunosuppressive treatment (immunosuppression).

In one embodiment, the presence of the gene therapy product and/or the expression of the functional microdystrophin, as well as the associated therapeutic benefits, are observed for up to 1 month, or 3 months or 6 months or even 1 year, 2 years, 5 years, 10 years, or even the whole life of the subject.

According to the invention, the subject is a mammal, preferably a human or a dog, but can also be a mouse, a rat or a nonhuman primate.

2017200015 03 Apr 2018 “Dystrophic disease” means a disease linked to a defect in the dystrophin gene. This defect can be deletions or mutations leading to low level of expression or absence of expression, introduction of a premature stop codon in the open reading frame, or the production of an inactive protein. The dystrophic diseases Duchenne and Becker muscular dystrophy (DMD/BMD) are caused by mutations of the dystrophin gene. Said mutations can result in the absence or a low level of dystrophin expression, or in the production of a partially or fully inactive, possibly truncated protein.

Subjects that could benefit from the compositions of the invention include all patients diagnosed with a muscular dystrophy or at risk of developing such a muscular dystrophy. A subject to be treated can then be selected based on the identification of mutations or deletions in the dystrophin gene by any method known to the one skilled in the art, including for example sequencing of the dystrophin gene, and/or through the evaluation of the dystrophin level of expression or activity by any method known to the one skilled in the art. Therefore, said subjects include both subjects already exhibiting symptoms of a dystrophic disease and subjects at risk of developing said disease. In one embodiment, said subjects include subjects already exhibiting symptoms of a dystrophic disease. In another embodiment, said subjects are ambulatory patients and early non-ambulant patients.

Such compositions are notably intended for gene therapy, particularly for the treatment of Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD), advantageously DMD.

A first target of the invention is to provide a safe (not toxic) treatment. A further aim is to provide an efficient treatment which allows to postpone, slow down or prevent the development of the disease, and possibly to ameliorate the phenotype of the patient which can be easily monitored at the clinical level.

In a subject, the composition according to the invention can be used:

- for ameliorating muscular function. Of particular interest are the skeletal muscles, but also the cardiac muscle and the diaphragm;

- for ameliorating gait;

- for ameliorating cardiac function;

- for ameliorating respiratory function;

- for ameliorating digestive function; and/or

2017200015 03 Jan 2017

- for prolonging survival, more generally to ameliorate the quality and the expectancy of life.

According to one aspect, the invention concerns a method for ameliorating muscular 5 function, gait, digestive function, cardiac function and/or respiratory function, and/or for prolonging survival, advantageously without adverse effects (cellular and/or humoral immune response), comprising administering to a subject in need thereof a therapeutic quantity of a gene therapy product as disclosed above.

Advantageously, said ameliorations are observed for up to 1 month after administration, 10 or 3 months or 6 months or 9 months, more advantageously for up to 1 year after administration, 2 years, 5 years, 10 years, or even for the whole life of the subject.

In one embodiment, said ameliorations results in reduced symptom severity and/or frequency and/or delayed appearance, wherein said symptom is chosen within the group consisting of frequent fall, inability to walk, dysphagia, cardiomyopathy, ptyalism, reduced motor skills (running, hopping, jumping), breathing abnormalities, pseudohypertrophy, lumbar hyperlodosis, and muscle stiffness.

An amelioration of said functions can be evaluated based on methods known in the art, e.g.:

- assessment of the percentage of muscle fibers expressing the dystrophin protein;

- walking tests;

- assessment of strength by dynamometer measurements;

- assessment of motor function of a precise limb by motor function measurements;

- assessment of global activity using a movement monitor;

- assessment of gait by accelerometric recording in 3 axes;

- assessment of cardiac function by echocardiographic, Doppler analyses and Speckle tracking analysis;

- assessment of respiratory function by evaluation of diaphragm kinetics;

- assessment of vital functions, especially cardiac, respiratory and digestive functions, by clinical follow-up;

- assessment of quality and expectancy of life by clinical score.

As illustrated in the examples, the claimed treatment allows improving the clinical state and the various parameters disclosed above in comparison with an untreated subject.

2017200015 03 Jan 2017

According to one embodiment, the present invention concerns a method of treatment of a dystrophic disease comprising administering to a subject the gene therapy product as disclosed above, wherein:

- at least 30% of the muscle fibers, advantageously 40%, more advantageously at least 50% of the muscle fibers express the dystrophin protein; and/or

- a clinical score is maintained at a level corresponding to at least 50% of the score of a healthy subject, advantageously at least 60% or even 70%.

Advantageously, said effects are observed for up to 1 month after administration, or 3 months or 6 months or 9 months, more advantageously for up to 1 year after administration, 2 years, 5 years, 10 years, or even more for the whole life of the subject.

As known in the art, the level of dystrophin expression in muscles is easily determined by the skilled person, advantageously by immunohistochemistry, e.g. by immunostaining of muscular biopsies with an anti-Dystrophin antibody as disclosed above. The calculation of clinical scores is also routine for the skilled person. As detailed above in relation with dogs, this score can be calculated based on dysphagia, breathing, ptyalism and global activity. Concerning patients, Bushby and Connor have e.g. listed clinical outcome measures for trials in Duchenne muscular dystrophy (Clin Investig (Lond). 2011; 1(9): 1217-1235).

The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are well within the purview of the skilled artisan. Such techniques are explained fully in the literature, such as, “Molecular

Cloning: A Laboratory Manual”, fourth edition (Sambrook, 2012); “Oligonucleotide Synthesis” (Gait, 1984); “Culture of Animal Cells” (Freshney, 2010); “Methods in Enzymology” “Handbook of Experimental Immunology” (Weir, 1997); “Gene Transfer Vectors for Mammalian Cells” (Miller and Calos, 1987); “Short Protocols in Molecular Biology” (Ausubel, 2002); “Polymerase Chain Reaction: Principles, Applications and

Troubleshooting”, (Babar, 2011); “Current Protocols in Immunology” (Coligan, 2002). These techniques are applicable to the production of the polynucleotides and polypeptides of the invention, and, as such, may be considered in making and practicing the invention. Particularly useful techniques for particular embodiments will be discussed in the sections that follow.

The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety.

2017200015 03 Jan 2017

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods.

EXPERIMENTAL EXAMPLES

The invention is further described in detail by reference to the following experimental examples and the attached figures. These examples are provided for purposes of illustration only, and are not intended to be limiting.

The results presented below have been obtained in the GRMD (Golden Retriever Muscular Dystrophy) dog model. It is the best animal model for dystrophic pathologies, in order to evaluate the potential of a gene therapy product, in terms of efficiency (therapeutic dose, stability, toxicity, ...) but also of immune response, before clinical trials.

Figure 1: Scheme of the full-length dystrophin (A), of various microdystrophins (B) and of the expression construct (C).

Figure 2: Study plan - General scheme of the systemic treatment in GRMD dogs.

Figure 3:

A/ Muscular biopsies obtained 3 months post rAAV2/8-SPc5.12-cMD vector administered by intravenous systemic delivery into the GRMD2 dog (ICI).

nJ m. biceps fern oris before injection b/ healthy dog c/ m, extensor carpi radialis right:

% of cMD + fibers (cMD detected in 82 % of the fibers)

2.8 vg/dg (vector genome per diploid genome) d/ m, extensor digitorum communis right:

59 % of cMD + fibers (cMD detected in 59 % of the fibers)

4.1 vg/dg e/ m, extensor carpi radialis left:

% of cMD + fibers (cMD detected in 62 % of the fibers)

6.2 vg/dg f/ m, extensor digitorum communis left:

% of cMD + fibers (cMD detected in 66 % of the fibers)

2.6 vg/dg

2017200015 03 Jan 2017

B/ Muscular biopsies obtained 8 months post rAAV2/8-SPc5.12-cMD vector administered by intravenous systemic delivery into the GRMD2 dog (ICI):

a/ m. biceps femoris right:

% of cMD + fibers (cMD detected in 58 % of the fibers)

l.Ovg/dg b/ m. biceps femoris left:

% of cMD + fibers (cMD detected in 56 % of the fibers)

0.8 vg/dg

Figure 4: Data on clinical score obtained in the GRMD cohort that has received 10¹⁴ vg/kg of rAAV2/8-SPc5.12-cMD vector systemic at the age of 2 months.

* means that the dog is no longer alive

Figure 5: Data on the Global gait index. Curves were calculated using the model built by Discriminant Analysis and the Data obtained for untreated GRMD and healthy dogs are represented. For the latters, the mean centroid curves and the 95% confidence intervals are shown.

Figure 6: Diaphragm Range of Motion (ROM) monitored on treated and untreated GRMD dogs. Healthy dogs display a ROM value between 90 and 110%.

Figure 7: IFNg ELISpot using canine gDys peptide pools (kinetics of PBMCs). Data were obtained in the GRMD Dog 2 (ICI) that has received 10¹⁴ vg/kg of rAAV2/820 SPc5.12-cMD vector systemic at the age of 2 months.

Figure 8: Detection of anti-dystrophin IgG antibodies by Western-Blot in injected dog sera. Data were obtained in the GRMD Dog 2 (ICI) that has received 10¹⁴ vg/kg of rAAV2/8-SPc5.12-cMD vector systemic at the age of 2 months. The reactivity of each serum was tested on cellular extracts of 293 cells transfected (or not) with a pCMV25 canine-MD (cgDys). Sera before injection (Day 0) and after injection (week 3, month

1.5, Month 2.5, month 4 and month 7.5) have been tested. Positive controls consisted in the anti-dystrophin antibody MANEX 1011C, and a positive canine serum (C+) from a GRMD dog immunized against dystrophin.

2017200015 03 Jan 2017

Materials and Methods:

1/ Animals

The evaluation of a fully systemic injection of the microdystrophin vector (rAAV2/8SPc5.12-cMD) has been performed in the GRMD dog model (Kornegay etal., Mamm Genome, 2012). Selected male dogs were genotyped for the DMD mutation, which consists of a single base change in the 3’ consensus splice site (A>G) of intron 6 of the dystrophin gene that provokes inaccurate mRNA processing.

Dogs were treated as shown in Table 1 below (without immunosuppression):

Dose	Timing of follow-up	Name of the dog	Date of injection	Date of euthanasia
					Still alive
		IMAGE	pDys 1	6.11.2013
				(17 months post-inj°)
	Long term	ICI		6.01.2014	Still alive
		(15 months post-inj°)
lE14vg/kg	7-8 months	ICE-T	pDys 3	28.08.2013	16.04.2014
	post-injection	JAFFAR	pDys 4	16.09.2014	May 2015
		JACADI	pDys 5	3.11.2014	July 2015

Control dogs correspond to non injected GRMD dogs and healthy dogs.

2/ Microdystrophin vector

The rAAV2/8-SPc5.12-cMD vector encodes an mRNA sequence-optimized canine dystrophin (cMD) under the control of a muscle-specific promoter (SPc5.12).

The construction of canine-specific, mRNA sequence-optimized cMD cDNA, incorporated deletions of rod domains 4-23 and exon 71-78 of the CT domain of dystrophin (AR4-R23; Figure 1), containing the last three amino acids of exon 79 of dystrophin followed by three stop codons and incorporating the SV40 poly adenylation site. cDNA sequence was modified to include a consensus Kozak sequence. An mRNA sequence was optimized based on transfer RNA frequencies in human and GC content

2017200015 03 Jan 2017 was increased to promote RNA stability. mRNA sequence optimization of microdystrophin (GENEART, Regensburg, Germany) resulted in the GC content being increased from 48% to 61% in the canine dystrophin and 23.6% of codons being modified as well. The size of the cMD gene cDNA is 3603 bp and the flanking inverted terminal repeat (ITR)-containing transgene cassette size of this vector is 4643 bp, which corresponds to 99.2% of the 4682 bp of wild-type-AAV2 genome length. 5’- and 3’untranslated regions of the dystrophin gene were removed to decrease the flanking ITR size of the dystrophin cassette. Expression was under the control of the muscle-specific synthetic promoter (SPc5-12) (Wang, B., et al., Gene Ther, 2008. 15(22): p. 1489-99).

This expression cassette (SEQ ID NO: 2 including the AAVITR, the Spc512 promoter, the canine MD cDNA and the SV40 PolyA) was demonstrated to result in widespread and stable dystrophin expression after intramuscular injections in the Duchenne beaglebased CXMDJ model (Koo, T., et al., J Gene Med, 2011. 13(9): p. 497-506). In addition, this construct improved muscle pathology and reduction of inflammatory responses in the target muscle tissue.

3/ Preparation of rAAV2/8-SPc5,12-cMD

The recombinant adeno-associated virus vector containing the canine microdystrophin cDNA regulated by the SPc5- 12 promoter, rAAV2/8-SPc5.12-cMD, was produced in a baculovirus/Sf9 system. Two baculovirus batches were generated, one expressing rep (encoding the AAV2 Rep protein) and cap (encoding the AAV8 Cap protein) AAV genes and the second being the AAV2 transfer vector. The viruses were produced, banked, and used to co-infect SF9 cells in 200-liter single-use bioreactor (Sartorius). After a three-day culture, cells are harvested, lysed, and the lysate processed by clarification, purification on an immunoaffinity column, concentration through tangential flow filtration, formulation, sterile filtering and filling. Purification is based on a commercial gel (AVB from GE Healthcare) carrying a single-chain antibody binding AAV1, AAV2, AAV3,

AAV5, AAV6, and AAV8. The process has an overall yield of >20%, and generates 145 units of 4.5 ml product with a viral titer >10° vg/ml.

2017200015 03 Jan 2017

4/ Systemic administration

GRMD dogs have been injected by systemic delivery with the therapeutic candidate (rAAV2/8-SPc5.12-cMD) vector. This pilot cohort was administered with 10¹⁴ vg/kg (total of around 5xl0¹⁴ vg/animal). The simple systemic injection was performed through a peripheral vein, in a cannulated cephalic vein, at a flow rate of 3 mL/min. Total injected volume was around 25 mL of vector preparation (5 ml/kg) representing 6 % total blood volume (10% being the recommended upper limit), which turned out to be very well tolerated.

The experimental animals were injected at the age of 2 months and are followed as shown in Table 1. They all were prescreened for the absence of AAV8 neutralizing factors in the serum. Prior the intravenous (IV) injection of the vector, GRMD dogs that exhibited profound weakness and/or swallowing impairment were discarded from the experiment. Immunosuppressive regiments were never used and the only medical care provided was restricted to maintain comfort and wellbeing of the animals. Appropriate regulatory documents (ethics and GMO handling) were obtained in due time. All procedures are carried out accordance with the Guide for the Care and Use of Laboratory Animals and approved by the ad hoc Animal Use and

Care Committee.

5/ Evaluation of the systemic treatment

Morbidity and mortality are assessed twice daily. Animals found dead would be submitted to necropsy in the presence of the pathologist and tissue samples collected when appropriate in attempt to systematically determine the cause of death.

Clinical and biological tolerance of the protocol

In all dogs, clinical laboratory parameters including electrolytes, kidney and liver function tests and complete blood counts are monitored regularly after injection. The clinical status of each dog, including cardiac, respiratory, digestive, locomotors and neurologic functions, are also carefully and weekly evaluated all along the protocol.

2017200015 03 Jan 2017

Assessment of vector shedding and vector biodistribution by Q-PCR

Vector shedding and vector biodistribution by Q-PCR are performed regularly until euthanasia on urine, serum, intermediate muscle biopsies, major skeletal muscles from the 4 limbs among flexors and extensors, heart and diaphragm, liver, spleen, kidneys, lymph nodes and testis. Extraction of rAAV DNA from fluids is done using the Qiamp Viral RNA mini-kit (Qiagen). rAAV is extracted from 140 pL of serum. 1/8 of the extraction (10 pL) is used for Q-PCR analysis. Extraction of genomic DNA (gDNA) from tissues is done using the Gentra Puregene kit (Qiagen) and Tissue Lyzer II (Qiagen). The concentration of each gDNA sample is determined using a nano10 spectrophotometer (Implen).

Quantitative PCR is conducted on a StepOne Plus (Applied Biosystem) using 50ng of gDNA in duplicates or 10 pL of fluid extracts. Vector copy numbers is determined using primers and probe designed to specifically amplify the SPc5.12-cMD cassette. gDNA copy numbers is determined using primers and probe designed to amplify the canine glucuronidase gene. For each sample, Ct (cycle threshold) values are compared with those obtained with different dilutions of linearized standard plasmids (containing either the SPc5.12-cMD cassette or the canine glucuronidase gene). Results are expressed in vector genome per diploid genome (vg/dg). For fluids, only the transgene specific Q20 PCR is performed and results are expressed in vector genome per pi of fluid extracted. The absence of Q-PCR inhibition in the presence of gDNA is previously checked by analyzing 10 pL of fluid extract or 50ng of gDNA extracted from spleen, testis, liver, kidney or skeletal muscle, spiked with different dilutions of standard plasmid.

Assessment of transgene expression in different tissues by Q-RT-PCR

Microdystrophin expression is assessed by Q-RT-PCR in multiple skeletal muscles, heart and diaphragm, liver, spleen, and any other tissue exhibiting high vector copy number. Briefly, total RNA is extracted from muscles, liver and spleen with TRIzol reagent (Invitrogen) and treated with RNAse-free DNAse I from the TURBO DNA30 free kit (Ambion) according to the manufacturer’s instructions. Reverse transcription is performed using random primers and an M-MLV reverse transcriptase (Invitrogen). A negative control without reverse transcriptase (RT-) is processed for each sample. Quantitative PCR is conducted on a StepOne Plus (Applied Biosystem) diluted cDNA in duplicates. The relative quantification of the cMD messengers is determined using primers designed to specifically amplify this sequence. The results are normalized by a Q-PCR analysis of the canine RPL32 (Ribosomal Protein L32) messenger, known to be similarly expressed in the different tissues of dog (Peters, I.R., et al.,. Vet Immunol

2017200015 03 Jan 2017

Immunopathol, 2007. 117(1-2): p. 55-66). The absence of Q-PCR inhibition in the presence of cDNA of muscle, liver and spleen is checked by analyzing diluted cDNA spiked with different dilutions of standard plasmid.

For each sample, Ct (cycle threshold) values are compared with those obtained with different dilutions of standard plasmids (containing the cMD expression cassette or the sequence of the canine RPL32 messenger). Results are expressed in relative quantities (RQ):

rq _ 2'^^ ' = 2Nt ^tarS^et (-¹ endogenous control)

Analysis of Dystrophin expression by Western blot

Using a specific Western-Blot analysis, the expression of microdystrophin in different muscles of the injected dogs is evaluated:

- In several skeletal muscles, as well as the heart and the diaphragm, sampled at euthanasia,

- In liver, spleen and any other tissues in which a high level of transgene copy numbers would be found, at euthanasia.

Total proteins are extracted from tissue samples. Protein extracts are separated on SDSPAGE, transferred on a nitrocellulose membrane. After Red Ponceau staining, membranes are blocked in 5% skim milk in TBS and hybridized with the antiDystrophin MANEX1011C antibody and with secondary anti-mouse IgG HRPconjugated antibody.

Analysis of Dystrophin expression by immunohistochemistry

By immunochemistry, microdystrophin expression is evaluated in the skeletal muscles of the injected dogs:

- In intermediate muscular biopsies,

- In all skeletal muscles, as well as the heart and the diaphragm, sampled at euthanasia,

- In liver, spleen, testes, kidneys and lymph nodes, sampled at euthanasia.

microdystrophin expression and localization are assessed by immunohistochemistry, microdystrophin polypeptide immunostaining is performed on transverse sections of each muscle using the mouse anti-Dystrophin antibody from Novocastra (NCL-DYSB). The restoration of the Dystrophin-associated proteins is evaluated by immunostaining of β-dystroglycan, β-sarcoglycan, gamma-sarcoglycan and Utrophin, including colocalization with laminin at the sarcolemal membrane.

2017200015 03 Jan 2017

Assessment of the local pathological pattern in the muscles

Pathology assessment is key to address the actual benefit of the gene therapy product at the target tissue level. Using morphometric analyses, the EC Board-certified pathologist evaluates the pathological pattern in the skeletal muscles of the injected dogs. These analyses are done on postural muscles with a majority of type I fibers (proximal limb muscles, paravertebral muscles); locomotor muscles with a majority of type II fibers (flexor and extensors from distal limb muscles); respiratory muscles, diaphragm, intercostal and masticatory muscles. Heart is evaluated extensively as well with the specific difficulty to apprehend fibers diameter due to unparalleled orientation.

Endomysial fibrosis is evaluated after immunohistochemical revelation of Collagen I (immunoperoxydase assay) and automatic measurement of the percentage of the labeled areas.

Total fibrosis is evaluated after immunohistochemical revelation of Collagen I (immunoperoxydase assay), on the same slides than endomysial fibrosis. An automatic measurement of the percentage of the total labeled areas is also performed.

Perimysial fibrosis is calculated by the difference between total fibrosis and endomysial fibrosis in the same fields of muscular tissue.

Anocytosis (variation of fibers diameter) is evaluated by manual morphometry: determination of the minimum fiber diameter on at least 200 myofibers and six fields per analyzed muscle cross-section.

Necrosis is evaluated by measurement of calcium accumulation, by an Alizarin Red staining. The percentage of labeled areas is measured after manual threshold. Regeneration is evaluated after immunohistochemical revelation myotubes with an antibody specific of a developmental Myosin Heavy Chain isoform (immunoperoxydase assay). The percentage of labeled areas is measured after manual threshold.

Inflammation is evaluated after immunohistochemical revelation of T and B lymphocytes and macrophages on the same slide (immunoperoxydase assay). The percentage of labeled areas is determined after manual threshold.

Assessment of the pathological pattern in the different tissues

Potential adverse side effects due to off target tissues (liver, spleen, kidney, ... ) is evaluated using HE staining and anatomopathology expertise in the different tissues of the dogs at euthanasia.

2017200015 03 Jan 2017

NMR imaging and spectroscopy indices of skeletal muscles

Non-invasive muscle imaging and spectroscopy indices are performed a week before euthanasia. The dogs are sent to Institute of Myology, Paris (Pierre Carlier’s team) and subjected to a 3T Siemens Trio scanner Nuclear Magnetic Resonance (NMR) to quantitatively and serially describe the dystrophic muscle abnormalities compared to untreated and healthy animals. In addition to that, P31 spectroscopy of the extensor carpi radialis is realized at 4T in a Bruker biospec scanner. Each individual measurement is positioned relative to the reference data during previous NMR studies of disease progression in groups of untreated and healthy dogs Thibaud, J.L., et al.,

Neuromuscul Disord, 2012. 22 Suppl 2: p. S85-99; Wary, C., et al., NMR Biomed, 2012. 25(10): p. 1160-9. Thoracic and pelvic/fore limbs are imaged in a 3T scanner. Standard and fat-saturated T1-, T2- and proton-density-weighted images are acquired as described in Thibaud, J.L., et al. (Neuromuscul Disord, 2007. 17(7): p. 575-84). A measurement of TI and a two-hour kinetic study of muscle enhancement after gadolinium-chelate injection are also performed. Ten indices that differ between healthy and untreated GRMD dogs have been identified, which allow interpreting the effect of the gene therapy treatment on large muscle territories.

Functional assessment: clinical grading

Clinical examination is also performed twice daily and includes food and water consumption, activity (global comportment, response to external stimuli) and physical appearance (face, fur, limbs). A full examination with body weight is performed on all animals during each anesthesia.

The general clinical status of the animals with respect to the muscle disease is evaluated by a clinical grading done weekly after injection, using a previously published protocol (Rouger, K., et al., Am J Pathol, 2011. 179(5): p. 2501-18). This evaluation includes 11 locomotion criteria and 6 items related to the general health status (including dysphagia, ptyalism, global activity and breathing). Each item is scored from 0 to 2, with 0 corresponding to the absence of symptoms and 2 to maximum severity. The global clinical score is expressed as the percentage of the maximum clinical score (defined as 100% for a healthy dog) and a tendency curve (mobile means order 3) is built to represent the clinical score evolution. The clinical score evolution obtained in the injected dogs is compared to the clinical score evolution of non-injected GRMD dogs.

2017200015 03 Jan 2017

Functional assessment: Gait analysis (muscular function)

Gait analysis quantified by Locometrix is performed twice a month. Locometrix® is a 3D accelerometric device composed of 3 orthogonally positioned accelerometers. This construction allows the recording of the accelerations along the dorso-ventral, cranio5 caudal and medio-lateral axes of the dogs. Speed, stride frequency, stride length, regularity, total power, dorso-ventral power, cranio-caudal power, medio-lateral power and force can be analyzed with this device, and several of these indices are modified during the progression of the disease in GRMD dogs (Barthelemy, I., et al., BMC Musculoskelet Disord, 2011. 12: p. 75).

Functional assessment: Cardiac function evaluation

Cardiac function of the treated dogs is evaluated monthly using echocardiographic and Doppler analysis, a sensitive approach allowing the detection of contractility defects. Data acquisition:

Conventional echocardiography and 2D color tissue Doppler imaging (TDI) are performed on conscious dogs in standing position monitored with a continuous ECG, using a Vivid 7 ultrasound unit equipped with 5-7.5 and 2-5MHz phased-array transducers (GE, Waukesha, WI), according to the recommendations from the American College of Veterinary Internal Medicine (Thomas, W.P., et al., J Vet Intern

Med, 1993. 7(4): p. 247-52). All data are transferred for offline analysis using a specific software (Echo Pac 5.4, GE) by two examiners who are unaware of the clinical status of the dogs. Several parameters are measured for the assessment of myocardial contractility as described below.

Conventional parameters: Left ventricular (LV) dimensions, posterior wall and interventricular septal wall thicknesses are measured.

Left ventricular fractional shortening and ejection fraction (Teichholz method) are calculated. Pulsed Doppler of the mitral valve inflow are used for measuring the ratio of early to late diastolic flow velocity (E/A).

Tissue Doppler imaging: Measurement of radial myocardial velocities and strain rate are obtained from a short-axis view at the level of the papillary muscles in the posterior wall and an apical 4-chamber view at the level of the basal portion of the septal and lateral walls.

Speckle tracking imaging: In a short-axis view, segmental strains in each of the 5 predefined segments are measured. Mean circumferential and radial are determined by calculating manually the mean of the measurements obtained. In the 4 chambers view, global longitudinal strains are measured automatically with a program that integrates

2017200015 03 Jan 2017 the measurements derived from the analysis of 6 automatically detected segments. Pre injection data and mock injected GRMD serve as references.

Functional assessment: respiratory function evaluation

Respiratory function is evaluated monthly and is done by using thoracic radioscopic acquisitions performed on conscious dogs. After extraction of the end-expiratory and end-inspiratory images, 2 indices are calculated:

- the caudal retraction index of the diaphragm (RI) reflects the retraction of the diaphragm;

- the diaphragm range of motion (ROM) reflects the mobility of the diaphragm: It is obtained after (i) superpostion of the 2 images obtained on end-inspiration and on end-expiration, (ii) measurement of the distance between the localization of the ventral point of the caudal vena cava foramen on each image, (iii) normalization of this distance by the length of the 13^th thoracic vertebra (T13).

These 2 indices are correlated with the retraction and the mobility of the diaphragm, which are modified during disease progression in GRMD dogs (Barthelemy, I., et al., Myology congress, 2011). The results obtained in the GRMD dogs are positioned relative to the results obtained in non-injected untreated animals.

Clinical follow-up of respiratory function:

Respiratory function is also evaluated via an observation of respiratory movements/cycles with their modification revealing some respiratory abnormalities, that can be the consequences of the diaphragm and other respiratory muscles weakness. Animal status with respect to the apparition and worsening of respiratory abnormalities is evaluated by clinical examination performed bi-monthly by a specialized veterinarian. In particular, the number and regularity of respiratory movements/cycles are evaluated.

Functional assessment: digestive function evaluation

Clinical follow-up of digestive function:

As seen in DMD patients, dysphagia (i.e. difficulty in swallowing) is a typical symptom of disease evolution in GRMD dogs, as a consequence of pronounced oral and pharyngeal muscular weakness (van den Engel-Hoek, J Neurol, 2013, 260(5): 1295303).

2017200015 03 Jan 2017

Animal status with respect to the apparition and worsening of dysphagia is evaluated by a clinical examination performed bi-monthly by a specialized veterinarian. In particular, tongue size, presence of abnormal quantities of saliva within the mouth, and the capacity of the animal to eat solid or soft food are evaluated.

Follow up of the immune responses

During the entire study, blood samples (plasma, serum and peripheral blood mononuclear cells-PBMC) from dogs enrolled in the study are harvested to monitor the:

- humoral immune response against rAAV8

- humoral immune response against microdystrophin

- cellular immune response against rAAV8

- cellular immune response against microdystrophin

- inflammatory immune response in the early times after injection

Blood samples are handled according to the French L2 biosafety requirements and are processed for hematology and clinical biochemistry. Dedicated serum samplings are regularly obtained for the following immunology assessments: (i) anti-AAV antibodies and anti-dystrophin antibodies; (ii) inflammatory cytokines measurement by Luminex;

(iii) complement activation. Whole blood was also collected prior and after treatment for isolation of the peripheral blood mononuclear cells (PBMC) and subsequent monitoring a potential cellular immune response against AAV and/or dystrophin polypeptide. Humoral immune responses to rAA V8 vector:

Dog sera is evaluated at different time points post-vector injection: (i) for the presence of IgG, and IgM specific to rAAV8 detected by customized ELISA; (ii) for the rAAV8 neutralizing capacity revealed by customized neutralizing assay.

Humoral immune responses to Dystrophin:

The detection of IgG anti-Dystrophin antibodies is routinely performed by Western-Blot analysis. Briefly, cellular extracts containing canine dystrophin protein are subjected to SDS-PAGE, and then transferred to a Hybond ECL nitrocellulose membrane. After an overnight saturation, membranes are incubated with experimental canine sera from injected animals. Subsequently, detection is performed by hybridization with peroxydase conjugated rabbit anti-dog IgG antibody, followed by enhanced chemiluminescence detection. Positive control consists in anti-Dystrophin MANEX 1011C antibody (Wolfson Center for Inherited Neuromuscular Diseases).

The cellular immune responses to AAV8 and dystrophin polypeptide are evaluated as follows: Briefly, IFN-γ ELISPOT assays are performed with lentiviral vectors (LV) encoding for either VP proteins of AAV8 or canine dystrophin polypeptide. LV vectors are used to transduce PBMC. A complementary approach using an overlapping peptide

2017200015 03 Jan 2017 library covering the canine sequence of canine dystrophin polypeptide is also used to stimulate lymphocytes.

Inflammatory immune responses (cytokines) are quantified by Luminex technology before and at different time points post-vector administration looking at IL2, IL4, IL6,

IL8, IL10, IL15, IFN and TNF.

Results:

As shown on Figure 2, 2-month old GRMD dogs have been injected with lxl0¹⁴vg/kg of the rAAV2/8-SPc5.12-cMD vector described above, by simple systemic injection through a peripheral vein. No clinical nor biochemical nor hematology adverse effects were ever detected immediately nor up to several months post vector administration.

Muscular biopsies:

Intermediate biopsies from several different muscles were obtained for the GRMD dogs, 3 and 8 months post systemic injection.

Following the methodology described above, the percentage of muscle fibers expressing the dystrophin polypeptide, 3 months post systemic delivery of the vector, was investigated. The results for GRMD Dog 2 are shown on Figure 3A.

Along with the percentage of fibers expressing the therapeutic transgene, the number of vector genomes per diploid cell (vg/dg) is indicated after following the methodology also described above. For an average of 2-4 vg/dg, the average percentage of fibers expressing dystrophin ranked from 59 to 82% on the biopsies (Figure 3 A c/ to f/), which was interpreted as very encouraging. One can notice the absence of major cell infiltration and a pretty remarkable preserved tissue architecture.

8 months post systemic delivery of the vector, for 1 vg/dg, the percentage of fibers expressing dystrophin was about 50% on the biopsies (Figure 3B).

2017200015 03 Jan 2017

All the data available are compiled in Table 2 below:

Timing	Muscle	pDys 1 (IMAGE)	pDys 2 (ICI)	pDys 3 (ICE-T)	pDys 4 (JAFFAR)	pDys 5 (JACADI)
% Dys i vg/dg	% Dys	vg/dg	% Dys ! vg/dg	% Dys	vg/dg	% Dys	vg/dg
Before njection	Biceps femoris	<0.5% ΐ <i! 003	<0,5%	<0.007	<0,5% \ <0.003	<0,5%	<0003	<0,5%	-'0 003
3 months p.i.	Ext. carpi radialis R	62% ! 1.3	82%	2.8	43% \ 2.2	71%	4,4	81%	.-: A·'
	Ext. digit, communis R	68% j Is	59%	4.1	31% i 20	73%	4.7'	23%	1.5
	Ext. carpi radialis L	40% i [ i	62%	6.2	61% | 2.6	20%	1.5	12%	2,8
	Ext. digit, communis L	40% 1 0.0	66%	2 -5	42% j 7.3	21%	1,0	11%	1.0
8 months p.i.	Biceps femoris R	N/A ΐ 0.S	58%	0	9% \ 7.0
	Biceps femoris L	N/A ΐ 06	56%	0.8	38% ί 7.3
14 months p.i.	Biceps femoris R	44% ΐ 0	44%
	Biceps femoris L	36% j 0.7	40%	1 4

N/A: not applicable because of the low quality of the biopsy

Moreover, a further quantification of the vector genome copies found in the tissues of 5 GRMD dog 3, 7,5 months post injection, is shown in the table below:

2017200015 03 Jan 2017

	Tissu	vg/dg
Skeletal muscles of the right forelimb	m. flexor carpi ulnaris	0,16
m. extensor digitorum communis	0,25
m. flexor digitorum superficialis	0,12
m. flexor carpi radialis	0,19
m. extensor carpi radialis	0,97
m. pectoralis	1,01
m. deltoideus	1,86

Skeletal muscles of the left forelimb	m. flexor carpi ulnaris	0,24
m. extensor digitorum communis	0,56
m. flexor digitorum superficialis	0,11
m. flexor carpi radialis	0,13
m. extensor carpi radialis	0,29
m. pectoralis	2,47
m. deltoideus	1,88

Skeletal muscles of the body	m. paravertebral lumbar	0,82
m. intercostales externi	0,35
m. rhomboideus cervicis	1,42
m. rectus abdominis	0,68

Skeletal muscles of the right hindlimb	m. biceps femoris	1,03
m.tibialis cranialis	1,70
m. semi—membranous	2,06
m. semi—tendinous	1,33
m. gluteus superficialis	0,56
m. vastus lateralis	0,46
m. sartorius	0,80
m. gastrocnemius lateralis	0,81
m. extensor digitorum longus	0,53
m. gracilis	0,22

Skeletal muscles of the left hindlimb	m. biceps femoris	1,26
m. tibialis cranialis	0,96
m. semi—membranous	0,39
m. semi—tendinous	0,15
m. gluteus superficialis	1,11
m. vastus lateralis	2,19
m. sartorius	0,30
m. gastrocnemius lateralis	0,83
m. extensor digitorum longus	0,25
m. gracilis	0,37

1,26

Diaphragm diaphragm

Heart	heart (right + left ventricles)	1,78
heart (septum + part of the atrioventricular node)	0,97

2017200015 03 Jan 2017

Table 3: Vector genome copies found in the muscles of GRMD3 at sacrifice (7,5 months post-injection).

In a very interesting manner, it is observed that even at this late time point, a significant amount of transgenic particles is detected in all the skeletal muscles of the body (even at distance of the injection site, i.e. the right cephalic vein), but also in the heart and in the diaphragm. This is in favor of an excellent biodistribution of the transgene within the whole organism.

Clinical evaluation:

Preliminary data on clinical evaluation of the 5 treated GRMD dogs was performed as described above against 8 other untreated age-matched GRMD dogs. Figure 4 shows, at different post vector injection time points, an improvement of the clinical score based essentially on dysphagia, breathing, ptyalism, global activity. 100% scoring corresponds to healthy individuals. Even if clinical outcomes may vary between treated individuals within the same group (as it is often the case between untreated GRMD), these results suggest that the treated GRMD animals exhibit so far a rather stable phenotype, better than the majority of the untreated animals. The clinical score evaluated in the treated dogs is maintained at a level corresponding to at least 50% of the maximal score obtained in healthy dogs (100%), with some animals being above 70%, whereas the clinical score of the large majority of the untreated animals rapidly dropped under 40% even less (Figure 4).

Remarkably, the clinical follow up shows that even at one year old, the treated GRMD dogs are able to run, to jump obstacles, to stand up on their hind limbs. This was never observed for the untreated GRMD dogs, for which life expectancy is rarely more than one year.

The data shown on Figure 4 also support an amelioration of the cardiac and respiratory functions in treated dogs and a prolonged survival in comparison with untreated dogs, together with an improved quality of life.

2017200015 03 Jan 2017

Gait characterization:

As mentioned above, a bi-monthly gait evaluation was performed using the Locometrix® device. Accelerometric was recorded in 3 axes: dorso-ventral (DV), medio-lateral (ML) and cranio-caudal (CC). The gait characterization by a statistical discrimant factor analysis of 7 gait variables (stride frequency, regularity, total power, cranio-caudal power, dorso-ventral power, medio-lateral power and stride length) is shown on Figure 5.

The results obtained in the injected dogs are positioned relative to the reference data collected during a previous 3D-accelerometers study of disease progression in a group of 25 untreated GRMD and 9 normal dogs (Barthelemy, I., et al., BMC Musculoskelet Disord, 2011. 12: p. 75).

Data show that pdys-treated GRMD dogs developed a global gait index that was very different and much improved to that observed for age-matched untreated GRMD dogs. They rapidly improved their gait performances to exhibited gait very close to that of healthy dogs, after only 3 to 4 months post-injection. From these data, it appears that the pdys-treated GRMD dogs present a gait that is close to healthy dogs of the same breed.

Cardiac and respiratory functions:

The clinical scores shown on Figure 4 support an amelioration of the cardiac and respiratory function.

More specifically, improved respiratory function is supported by Figure 6 which, despite a significant variability among dogs, reveals superior values for the ROM indice in the treated GRMD dogs, in connection with an improved mobility of the diaphragm.

These data also corroborate the clinical follow up of the dogs reported in Table 4 below:

2017200015 03 Jan 2017

	Age of respiratory abnormalities appearance
pDys 1 (IMAGE)	19 months
pDys 2 (ICI)	None
pDys 3 (ICE-T)	None
pDys 4 (JAFFAR)	None
pDys 5 (JACADI)	None
GRMD Control 1 (1AMES)	7 months
GRMD Control 2 (1ESSY)	7 months
GRMD Control 3 (10SS)	6 months
GRMD Control 4 (EBOUGE)	6 months
GRMD Control 5 (FELIX)	4 months
GRMD Control 6 (FIASKO)	7 months

Respiratory abnormalities in GRMD dogs are characterized by a modification of the respiratory movements/cycles. Like in DMD patients, these abnormalities are the consequence of diaphragm and other respiratory muscle weakness. Table 4 reveals a delay or even suppression in the apparition of respiratory abnormalities in the treated GRMD (pDys) dogs.

Digestive functions:

Dysphagia (difficulty in swallowing) is a typical symptom of disease evolution in GRMD dogs. Like in DMD patients, dysphagia is the consequence of pronounced oral and pharyngeal muscular weakness.

A possible advantage of the treatment on digestive functions has been investigated and the results are reported in Table 5 below:

	Age of dysphagia appearance	Severity
pDys 1 (IMAGE)	12 months	10.2 months +/2.0 months	Weak
pDys 2 (ICI)	12 months	Very weak
pDys 3 (ICE-T)	10 months	Weak
pDys 4 (JAFFAR)	10 months	Weak
pDys 5 (JACADI)	7 months	Weak
GRMD Control 1 (1AMES)	8 months	6.2 months +/-1-3 months	Marked
GRMD Control 2 (1ESSY)	4 months	Severe
GRMD Control 3 (10SS)	6 months	Marked
GRMD Control 4 (EBOUGE)	6 months	Weak
GRMD Control 5 (FELIX)	6 months	Very weak
GRMD Control 6 (FIASKO)	7 months	weak

2017200015 03 Jan 2017

This clinical follow up reveals a delay in the apparition of dysphagia in the treated GRMD (pDys) dogs, with less severe symptoms.

Immune response / Toxicity:

The detection of the protein, 3 and 8 months post injection (Figure 3), as well as the good clinical scores shown on Figure 4, indicate the absence of adverse and deleterious immune responses to the recombinant AAV vector and to the microdystrophin.

The muscle biopsies (Figure 3), as well as the good clinical scores shown on Figure 4, support the absence of toxicity of the gene therapy product.

In terms of biosafety, the cellular immune response against cMD was evaluated, by interferon gamma Elispot using cMDYF peptides pools incubated on a kinetic of PBMCs (Figure 7). Whatever the injected dose, none of the injected animals exhibited a detectable secretion of Interferon gamma, suggesting an absence of cellular immune response against cMDYF.

The humoral immune response against cMD was also evaluated by an immuno-western20 blot (Figure 8). All the available results are compiled in Table 6 below:

	Before injection	Month +0.5	Month +1.5	Month +2	Month +4	Month +7.5
1E14 vg/kg	pDys 1	Nd	Nd	++	Nd	Nd	Nd
pDys 2	Nd	+	++	++	+	Nd
pDys 3	Nd	Nd	Nd	Nd	Nd	Nd
pDys 4	Pending	Pending	Pending	Pending	Pending	Pending
pDys 5	Pending	Pending	Pending	Pending	Pending	Pending

2017200015 03 Jan 2017

Here, the presence of anti-pdystrophin antibodies was detected in 2 out of 5 dogs injected with 10¹⁴vg/kg of the AAV-cMD vector. Of importance, this humoral immune response against the cMD is only transient (maximal range of detection = between 2 weeks and 4 months post-injection) and doesn’t seem to be associated to any clinical deleterious effect, suggesting that an immune tolerance could occur in these animals.

Survival:

Prolonged survival clearly appears from Figure 4:

- at age 8-9 months, only 2 over 8 untreated GRMD dogs are still alive. On the contrary all the treated GRMD dogs are still alive and healthy;

- in a general manner, the life expectancy of untreated GRMD dogs is around 12 months with a very bad clinical state at this age. On the contrary, the 2 treated GRMD dogs tested for long-term follow up (pDys 1 and 2) remain alive after this deadline (with an age of 19 and 17 months, respectively) and are in a good clinical state.

Therapeutic dose:

This study reveals that 10¹⁴ vg/kg, a relatively low dose for systemic administration, is an appropriate dose in terms of efficiency and toxicity in dogs.

CONCLUSIONS:

Altogether, these functional data correlated well with a substantial expression of dystrophin polypeptide (>50 % microdystrophin-expressing fibers) on intermediate muscle biopsies. They show the therapeutic effect of the MD microdystrophin construct and support that the systemic delivery may be beneficial to halt/reduce the progression of the disease. The results obtained from this systemic pilot cohort of GRMD indicate that several outcome measures from molecular, pathology and functional aspects support the systemic gene therapy in humans.

This study brings the proof of concept that the SPc5.12-cMD therapeutic cassette encoding for a sequence optimized microdystrophin and encapsidated in the AAV8 capsid provides clinical benefit to the dog model of the Duchenne myopathy after systemic intravenous administration of a single dose. Not only was the microdystrophin polypeptide highly expressed in multiple muscles but it also resulted in gait

2017200015 03 Apr 2018 improvement and improved clinical outcome measures, prolonged survival, without adverse immune response. To the knowledge of the inventors, this is the first report of so encouraging and surprising results, especially in the context of a systemic administration.

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgement of any form of suggestion that such prior art forms part of the common general knowledge.

It will be understood that the term “comprise” and any of its derivatives (eg comprises, comprising) as used in this specification is to be taken to be inclusive of features to which it refers, and is not meant to exclude the presence of any additional features unless otherwise stated or implied

2017200015 03 Apr 2018

Claims (18)

1. THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

   1. A method of treating a dystrophic disease selected from Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) in a human or dog subject, said method comprising systemically administering to the subject a composition comprising a gene therapy product, wherein said gene therapy product comprises an adeno-associated viral (AAV) vector which harbors a nucleic acid sequence encoding a AR4-R23/ACT microdystrophin.
2. 2. A method according to claim 1, wherein the composition is administered by intravenous injection.
3. 3. A method according to claim 1 or 2, wherein the nucleic acid sequence encoding the microdystrophin is of human or canine origin.
4. 4. A method according to any one of claims 1 to 3, wherein expression of the nucleic acid sequence encoding the microdystrophin is under the control of a muscle specific promoter.
5. 5. A method according to any one of claims 1 to 4, wherein the gene therapy product comprises a sequence 90% homologous to SEQ ID NO: 1 or SEQ ID NO: 2.
6. 6. A method according to claim 5, wherein the gene therapy product comprises a sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
7. 7. A method according to any one of claims 1 to 6, wherein the AAV vector is an AAV of serotype 2, 8 or 9.
8. 8. A method according to claim 7, wherein the AAV vector is an AAV8 vector.
9. 9. A method according to claim 7, wherein the AAV vector is an AAV2/8 vector.
10. 10. A method according to any one of claims 1 to 9, wherein the step of administering the composition comprises administering a dose less or equal to 10¹⁵ vg/kg.
11. 11. A method according to any one of claims 1 to 9, wherein the step of administering the composition comprises administering a dose between 10^{12 *} vg/kg and 10¹⁴ vg/kg.
12. 12. A method according to any one of claims 1 to 10, wherein the step of administering the composition comprises administering a single dose of the composition.

    2017200015 03 Apr 2018
13. 13. A method according to any one of claims 1 to 12, wherein the method ameliorates muscular function.
14. 14. A method according to any one of claims 1 to 13, wherein the method ameliorates cardiac function.
15. 15. A method according to any one of claims 1 to 14, wherein the method ameliorates respiratory function.
16. 16. A method according to any one of claims 1 to 15, wherein the method ameliorates digestive function.
17. 17. A method according to any one of claims 1 to 16, wherein the method ameliorates gait.
18. 18. A method according to any one of claims 1 to 17, wherein the method ameliorates quality and/or expectancy of life.

    1 /6

    2017200015 03 Jan 2017

    A/

    B/

    NOS

    Fitii iength dystrophin

    SynEfcrs

    ft®e reKtystFOphins SJOytMS _jaag^ng^ JB ΛίΜ H%2 3 ^bsmr»_m .ΐ£ζί·0&Ί .... Λ3Ϊ8Β ^!5S$g|||^ &3&S0 ^^^BBaaaaaaBa..... ww ww .....

    C/

    SPC512

    5’ITR promoter skeletal/cardiac muscles

    ossi 1 n 1 2 3 1 1 24 n B CR

    sdddddNCCCCC©

    PA

    3’ITR

    Figure 1

    2/6

    2017200015 03 Jan 2017

    Intravenous injection of rAAV8-canine_pDys

    Weekly grading (clinical evaluation) Bi-monthly Loeometrix® (gait evaluation) Monthly thoracic radioscopy Monthly echocardiography

    SISfMSs

    -2 months >4

    +.... months

    Evaluation of the immune response (humoral and cellular anti-AAV and anti-Dys)

    KMeasuteSehidtflMD-eiKuJatihg-hiciiriarker's-levelSK k'DystrophiniexpressionHpattern Jn'the'rnusGte&:of :the'w:hoieHt>oHy'(VV:B<:iF)2:2:2:2:2:2:

    Figure 2

    3/6

    2017200015 03 Jan 2017

    A/

    m„ biceps femoris before injection

    B/

    Figure 3

    4/6

    2017200015 03 Jan 2017 s§ ioo%

    3054 §054

    70« «0«

    50% i

    40%

    3054

    2054

    1054

    0%

    10 12 Age Aiionihsj

    14 IS IS 20

    Figure 4

    F2

    Vector (rejection

    Age in months 4 6

    H jiDys l^E14vg/kg (N=5)

    FI

    Figure 5

    5/6

    2017200015 03 Jan 2017

    Figure 6

    Before injection Month +1 Month +2 Month +3

    Figure 7

    2017200015 03 Jan 2017

    6/6

    :< : ; X ; ; : : lu : i C+ i*i c+ Day ί Wk i Mo § ; (dog Mo Mo / Mo / : 1 i (dog o ; +3 ; +1.5 i s i Serum) + 2 5 . Cellular extract —..........- + 4 ί +7.5 i : ; serum) .·; + .^k+ . *T ’+ . ’ 4r .₊ _ i 777TT* ·+ ’+ . ' <- cpDys (137kDa)

    Figure 8

    SEQUENCE LISTING

    2017200015 03 Jan 2017 <110> GENETHON

    ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE <120> EFFICIENT SYSTEMIC TREATMENT OF DYSTROPHIC PATHOLOGIES <130> G143-B-43539 PCT <150> EP14174848.3 <151> 2014-06-27 <150> PCT/EP2015/058964 <151> 2015-04-24 <160> 8 <170> BiSSAP 1.3 <210> 1 <211> 4640 <212> DNA <213> Artificial Sequence <220>

    <223> AAV_ITR_Spc512-human MD1 <400> 1 gcgcgctcgc tcgctcactg aggccgcccg ggcaaagccc gggcgtcggg cgacctttgg 60 tcgcccggcc tcagtgagcg agcgagcgcg cagagaggga gtggccaact ccatcactag 120 gggttccttg tagttaatga ttaacccgcc atgctactta tctacgtagc catgctctag 180 acatggctcg acagatcgag ctccaccgcg gtggcggccg tccgccctcg gcaccatcct 240 cacgacaccc aaatatggcg acgggtgagg aatggtgggg agttattttt agagcggtga 300 ggaaggtggg caggcagcag gtgttggcgc tctaaaaata actcccggga gttattttta 360

    2017200015 03 Jan 2017 gagcggagga

    420 ggtgtccgcc

    480 gataaaaggc

    540 agctctagaa

    600 gaagtggagg

    660 aacgcccagt

    720 gatggcagga

    780 aagggcagca

    840 aacaacaacg

    900 ctgaccctgg

    960 aacatcatgg

    1020 cagagcacca

    1080 ggcctggccc

    1140 gtggtgtgtc

    1200 cagctgggca

    1260 atggtggaca ctcggccggg tccggggccg ctagtggatc actgctacga tcagcaagtt gactgctgga ccagagtgca tggacctggt gcctgatctg ccggcctgca gaaactaccc tgaacgccct agcagagcgc tcgagaagct cccaaatatg gccgcattcc gcggcggccc ccccgggctg gagagaggac cggcaagcag tctgctggag cgccctgaac gaatatcggc gaacatcatc gcagaccaac ccaggtgaac gatccacagc cacccagaga gctggacccc gcgacggttc tgggggccgg acgagctacc caggaattcg gtgcagaaga cacatcgaga ggactgaccg aacgtgaaca agcaccgaca ctgcactggc agcgagaaga gtgatcaact cacagacccg ctggagcacg gaggacgtgg ctcacccgtc gcggtgctcc cggaggagcg ccaccatgct aaaccttcac acctgttcag gccagaagct aggccctgag tcgtggacgg aggtgaagaa tcctgctgag tcaccacctc acctgttcga ccttcaacat acaccaccta gccatatttg cgcccgcctc ggaggcgcca gtggtgggag caagtgggtg cgacctgcag gcccaaggag agtgctgcag caaccacaag cgtgatgaag ctgggtgagg ctggagcgac ctggaacagc cgccagatac ccccgacaag

    2017200015 03 Jan 2017 aaaagcatcc

    1320 gaggccatcc

    1380 ttccagctgc

    1440 tatgagagaa

    1500 tacgtgacca

    1560 gaggacaaga

    1620 accgccctgg

    1680 ggcgagatca

    1740 atgatggatc

    1800 ctgatcggca

    1860 ctgctgaaca

    1920 caccgcgtgc

    1980 aagaccgagg

    2040 ctgaagagac

    2100 cgcgtgaaca

    2160 tgatgtatat aggaagtgga accaccagat ccagcagccc cctccgaccc gcttcggcag aggaagtgct gcaacgacgt tgaccgccca ccggcaagct gcagatggga tgatggacct agcggaccag aggtgcagca gcctgaccca tacctctctg aatgctgccc gcactatagc caagcccaga caccagaagc cagcctgatg gtcttggctg ggaagtggtg ccagggcaga gagcgaggac gtgcctgaga gcagaaccag aaagatggag gcacaaagtg catggtggtc tttcaggtgc aggcccccca cagcagatca ttcaagagct cccttcccca gagagcgaag ctgtccgccg aaggaccagt gtgggcaata gaggagaccg gtggccagca aagctgaagg gaggagcccc ctgcaggagg gtggtggacg tgccccagca aagtgaccaa ccgtgtccct acgcctacac gccagcacct tgaacctgga aggacaccct tccacaccca tcctgcagct aagtgcagga tggagaagca agctgaacga tgggccccga acctggaaca agagcagcgg ggtgtccatc ggaggagcac ggcccagggc ccaggccgcc ggaggccccc cagataccag gcaggcccag cgagggctac gggcagcaag gcagatgaac gagcaacctg ctggctgacc cctggaggac ggagcaggtg cgaccacgcc

    2017200015 03 Jan 2017 acagccgccc

    2220 tggaccgagg

    2280 gaggagcagt

    2340 cacaccaccg

    2400 ctgaaggccg

    2460 gacctgctgt

    2520 aatttcgccc

    2580 agccaggccg

    2640 accacagtga

    2700 cccccccctc

    2760 caggaagcca

    2820 tggcagcctg

    2880 gccctgcggg

    2940 agacagctga

    3000 ctgaacaccc

    3060 tggaagagca acagatgggt gcctgtttag gcttcaagga atctggagaa ccaccctgaa ggtgctggga tgaccaccac ccaccaggga agaagaagcg ccgacgagct tgggcgatct gcgagatcgc ccaccctggg ggtggaaact gctgaaagtg gctgctgcag cgcctggctg ccagaacgag gaaaaagcag gaacaagagc caatctggtg ccagcccagc gcagatcctg gcagatcaca ggacctgaag gctgatcgac ccccctgaag catccagctg gctgcaggtg ctgggcgaca gacatcctgc agcgagaagg atgctgagca agcatgggca gtgacccaga cagaaactgg ctgacacaga gtgaagcacg gtggacaccc ctgagacagg agcctgcagg gagaatgtga agcccctaca gccgtggagg gatgggccaa tgaagtggca aggacgccgt gcctgcagaa agctgtactc aaaccgaggc agaagagcac ccaccgtgat cccaggagga tggagagact ccgaagtgat accacctgga gccacgtgaa atctgagcac atagagtgag catctgccgg gagactgaca gaacaagatc gctggccgtg cctgaagcag ctggctggac cgcccagatc ggagaccgtg gctgccccct gcaggagctg caagggcagc gaaagtgaag cgacctggcc cctggaagat gcagctgcac

    2017200015 03 Jan 2017 gaggcccaca

    3120 ccctgggaga

    3180 accacctgct

    3240 aatgtgcggt

    3300 tgcctggacc

    3360 cagaacgacc

    3420 cggctggagc

    3480 aattggctgc

    3540 aagaccggca

    3600 aagcaggtgg

    3660 gatagcatcc

    3720 gagccctctg

    3780 ctgttcctgg

    3840 agagtggccg

    3900 cccatcatcg

    3960 gagacttcgg gagccatctc gggaccaccc tcagcgccta tgctgagcct agcccatgga aggagcacaa tgaacgtgta tcatcagcct ccagcagcac agatccctag tgaggagctg attggatgag ccgccgagac gcttccggta ccctgcctcc ccccaacaaa taagatgacc cagaaccgcc gagcgccgcc cattctgcag caacctggtg cgacaccggc gtgcaaggcc cggcttctgc gcagctgggc cttccagttc gctggagccc cgccaagcac caggagcctg cagcacttcc gtgccctact gagctgtacc atgaagctgc tgcgacgccc atcatcaact aacgtgcccc aggaccggca cacctggagg gatcagagga gaagtggcca gccaacaaca cagagcatgg caggccaagt aagcacttca tgagcaccag acatcaacca agagcctggc ggagactgca tggaccagca gcctgaccac tgtgcgtgga gaatcagagt ataagtaccg gactgggcct gctttggcgg agcccgagat tgtggctgcc gcaacatctg actacgacat cgtgcagggc cgagacccag cgacctgaac gaaggccctg caacctgaag catctacgat catgtgcctg gctgtccttc ctacctgttc gctgctgcac cagcaacatc cgaggccgcc tgtgctgcac caaggagtgc ctgccagagc

    2017200015 03 Jan 2017 tgctttttca gcggcagagt ggccaagggc cacaagatgc actaccccat 4020 tgcaccccca ccacctccgg cgaggatgtg agagacttcg ccaaagtgct 4080 ttccggacca agcggtactt tgccaagcac cccaggatgg gctacctgcc 4140 gtgctggagg gcgacaacat ggagaccgac accatgtgat gatgagcggc 4200 tagtgagggt taatgcttcg agcagacatg ataagataca ttgatgagtt 4260 acaactagaa tgcagtgaaa aaaatgcttt atttgtgaaa tttgtgatgc 4320 tttgtaacca ttataagctg caataaacaa gttaacaaca acaattgcat 4380 tttcaggttc agggggagat gtgggaggtt ttttaaagca agtaaaacct 4440 ggtaaaatcc gataaggact agagcatggc tacgtagata agtagcatgg 4500 attaactaca aggaacccct agtgatggag ttggccactc cctctctgcg 4560 ctcactgagg ccgggcgacc aaaggtcgcc cgacgcccgg gctttgcccg 4620 gtgagcgagc gagcg

    4640 ggtggagtac gaagaataag cgtgcagacc cgcttccctt tggacaaacc tattgcttta tcattttatg ctacaaatgt cgggttaatc cgctcgctcg ggcggcctca <210> 2 <211> 4643 <212> DNA <213> Artificial Sequence <220>

    <223> AAV_ITR_Spc512-canine MD1

    2017200015 03 Jan 2017 <400> 2 gcgcgctcgc 60 tcgcccggcc

    120 gggttccttg

    180 acatggctcg

    240 cacgacaccc

    300 ggaaggtggg

    360 gagcggagga

    420 ggtgtccgcc

    480 gataaaaggc

    540 agctctagaa

    600 gaagtggagg

    660 aacgcccagt

    720 gatggcagga

    780 aagggcagca

    840 aagaacaacg

    900 tcgctcactg tcagtgagcg tagttaatga acagatcgag aaatatggcg caggcagcag atggtggaca ctcggccggg tccggggccg ctagtggatc actgctacga tcagcaagtt gactgctgga ccagagtgca tggacctggt aggccgcccg agcgagcgcg ttaacccgcc ctccaccgcg acgggtgagg gtgttggcgc cccaaatatg gccgcattcc gcggcggccc ccccgggctg gagagaggac cggcaagcag tctgctggag cgccctgaac ggatatcggc ggcaaagccc cagagaggga atgctactta gtggcggccg aatggtgggg tctaaaaata gcgacggttc tgggggccgg acgagctacc caggaattcg gtgcagaaga cacatcgaga ggactgaccg aacgtgaaca agcaccgaca gggcgtcggg gtggccaact tctacgtagc tccgccctcg agttattttt actcccggga ctcacccgtc gcggtgctcc cggaggagcg ccaccatgct aaaccttcac acctgttcag gccagaagct aggccctgag tcgtggacgg cgacctttgg ccatcactag catgctctag gcaccatcct agagcggtga gttattttta gccatatttg cgcccgcctc ggaggcgcca gtggtgggag caagtggatc cgatctgcag gcccaaggag agtgctgcag caaccacaag

    2017200015 03 Jan 2017 ctgaccctgg

    960 aacatcatgg

    1020 cagagcacca

    1080 ggcctggccc

    1140 gtggtgtgtc

    1200 cagctgggca

    1260 aaaagcatcc

    1320 gaggccatcc

    1380 ttccagctgc

    1440 tatgagagag

    1500 gcctacgtga

    1560 cctgaggata

    1620 cagaccgccc

    1680 cagggcgaga

    1740 tacatgatgg

    1800 gcctgatctg ccggcctgca gaaactaccc tgaacgccct agcagagcgc tcgagaagct tgatgtatat aggaagtgga accaccagat cccctagcag ccacctccga agagcttcgg tggaggaagt tcagcaacga acctgaccag gaacatcatc gcagaccaac ccaggtgaac gatccacagc cacccagaga gctggacccc taccagcctg aatgctgccc gcactatagc ccccaagccc ccccaccaga cagaagcctg gctgtcttgg cgtggaagaa ccaccagggc ctgcactggc agcgagaaga gtgatcaact cacagacccg ctggagcacg gaggacgtgg ttccaggtgc aggcccagca cagcagatca cggttcaaga agccccctgc accgagaccg ctgctgtccg gtgaaggagc agagtgggca aggtgaagaa tcctgctgag tcaccacctc acctgttcga ccttcaacat ccaccaccta tgccccagca aagtgaccag ccgtgtccct gctacgccta ccagccagca aggccaacct ccgaggacgc agttccacac acgtgctgca cgtgatgaag ctgggtgagg ctggagcgac ctggaacagc cgccaagtac ccccgacaag ggtgtccatc ggaggagcac ggcccagggc cacccaggcc cctggagacc ggatagctac cctgcaggcc ccacgagggc gctgggcagc

    2017200015 03 Jan 2017 cagctgatcg

    1860 aacctgctga

    1920 ctgcacaaag

    1980 accaagacag

    2040 gacctgaaga

    2100 gtgcgcgtga

    2160 gccacagccg

    2220 cggtggaccg

    2280 accgaggagc

    2340 atccacacca

    2400 gtgctgaaaa

    2460 caggacctgc

    2520 gataatagcg

    2580 atcagccagg

    2640 gtgaccatgg

    2700 gcaccggcaa acagcagatg tgctgatgga aggagcggac ggcaggtgca acagcctgac ccctggaaga aggacagatg agtgcctgtt ccggcttcaa ccgacctgga tgagcgccct ctcagagatg ccgtgaccac tgaccaccag gctgagcgag ggagtgcctg tctgcagaac ccggaagatg gcagcataag ccacatggtg gcagctgaaa ggtgctgctg tagcgcctgg ggaccagagc gaagaaaaag gaagaacacc ggataatctg cacccagccc ggagcacatc gacgaggaga agagtggcca cagcagctga gagaaggagc gtcctgcagg gtcgtggtgg gtgctgggcg caggacatcc ctgagcgaga gaagtgctgt cagaccatgg gtggtggccc gtgcagaaac agcctgacac ctggtgaagc ccgaagtgca gcatggagaa aggagctgaa ccctgggccc aggatctgga acgagagcag gcagatgggc tgctgaagtg aggaggacgc ccaacctgca acaagctgtg acaagatgga tggagaagag agaccaccgt acgcccagga ggaacagatg gcagagcaac cgactggctg tgacatcgag gcaggagcag cggcgaccac caatatctgc gcagagattc cgtgaacaag gaagctggcc cagcctgaac ggcctggctg cagcgcccag gatggagacc ggagctgccc

    2017200015 03 Jan 2017 cctccccccc

    2760 ctgcaggaag

    2820 agctggcagc

    2880 aaggccctgc

    2940 gccagacagc

    3000 gatctgaaca

    3060 cacgaggccc

    3120 ggcccctggg

    3180 cagaccacct

    3240 aacaatgtgc

    3300 ctgtgcctgg

    3360 aagcagaacg

    3420 gatcggctgg

    3480 ctgaattggc

    3540 ttcaagaccg

    3600 ctcagaagaa ccaccgacga ctgtgggcga ggggcgagac tgaccaccct cccggtggaa acagagactt agagagccat gctgggacca ggttcagcgc acctgctgtc accagcccat agcaggagca tgctgaacgt gcatcatcag gcggcagatc gctggacctg tctgctgatc cacccccctg gggcattcag actgctgcag cggccctgct cagccccaac ccctaagatg ctacagaacc cctgagcgcc ggatatcctg caacaacctg gtacgacacc cctgtgcaag atcgtggatg aagctgagac gacagcctgc aaggagaacg ctgagcccct gtggccattg tctcagcatt aaagtgccct accgagctgt gccatgaagc gcctgcgacg caggtgatca gtgaacgtgc ggcaggaccg gcccacctgg ccctggagag aggccgaagt aggaccacct tgtcctacgt acaacctgaa aggaccggat tcctgagcac actacatcaa accagagcct tgcggagact ccctggacca actgcctgac ccctgtgcgt gcagaatcag aggataagta actgcaggag gatcaagggc ggagaaagtg gaacgacctg caccctggag caggcagctg cagcgtgcag ccacgagacc ggccgacctg gcagaaggcc gcacaacctg caccatctac ggacatgtgc agtgctgtcc ccgctacctg

    2017200015 03 Jan 2017 ttcaagcagg

    3660 cacgatagca

    3720 atcgagccct

    3780 gccctgttcc

    3840 cacagagtgg

    3900 tgccccatca

    3960 agctgctttt

    4020 tactgcaccc

    4080 aagttccgga

    4140 accgtgctgg

    4200 ctttagtgag

    4260 accacaacta

    4320 ttatttgtaa

    4380 atgtttcagg

    4440 tgtggtaaaa

    4500 tggccagcag tccagatccc ctgtgaggag tggattggat ccgccgccga tcggcttccg tcagcggcag ccaccacctc ccaagcggta agggcgacaa ggttaatgct gaatgcagtg ccattataag ttcaggggga tccgataagg caccggcttc taggcagctg ctgcttccag gaggctggag gaccgccaag gtacaggagc agtggccaag cggcgaggat ctttgccaag catggagacc tcgagcagac aaaaaaatgc ctgcaataaa gatgtgggag actagagcat tgcgatcaga ggcgaagtgg ttcgccaaca ccccagagca caccaggcca ctgaagcact ggccacaaga gtgagagact caccccagga gacaccatgt atgataagat tttatttgtg caagttaaca gttttttaaa ggctacgtag ggagactggg ccagctttgg acaagcccga tggtgtggct agtgcaacat tcaactacga tgcactaccc tcgccaaagt tgggctacct gatgatgagc acattgatga aaatttgtga acaacaattg gcaagtaaaa ataagtagca cctgctgctg cggcagcaac gatcgaggcc gcctgtgctg ctgcaaggag catctgccag catggtggag gctgaagaat gcccgtgcag ggccgcttcc gtttggacaa tgctattgct cattcatttt cctctacaaa tggcgggtta

    2017200015 03 Jan 2017 atcattaact acaaggaacc cctagtgatg gagttggcca ctccctctct gcgcgctcgc

    4560 tcgctcactg aggccgggcg accaaaggtc gcccgacgcc cgggctttgc ccgggcggcc 4620 tcagtgagcg agcgagcgcg cag

    4643 <210> 3 <211> 1197 <212> PRT <213> Artificial Sequence <220>

    <223> human MD1 <400> 3

    Met Leu Trp Trp Glu Glu Val Glu Asp Cys Tyr Glu Arg Glu Asp Val 1 5 10 15 Gin Lys Lys Thr Phe Thr Lys Trp Val Asn Ala Gin Phe Ser Lys Phe 20 25 30 Gly Lys Gin His Ile Glu Asn Leu Phe Ser Asp Leu Gin Asp Gly Arg 35 40 45 Arg Leu Leu Asp Leu Leu Glu Gly Leu Thr Gly Gin Lys Leu Pro Lys 50 55 60 Glu Lys Gly Ser Thr Arg Val His Ala Leu Asn Asn Val Asn Lys Ala 65 70 75 80 Leu Arg Val Leu Gin Asn Asn Asn Val Asp Leu Val Asn Ile Gly Ser 85 90 95 Thr Asp Ile Val Asp Gly Asn His Lys Leu Thr Leu Gly Leu Ile Trp 100 105 110 Asn Ile Ile Leu His Trp Gin Val Lys Asn Val Met Lys Asn Ile Met 115 120 125 Ala Gly Leu Gin Gin Thr Asn Ser Glu Lys Ile Leu Leu Ser Trp Val 130 135 140 Arg Gin Ser Thr Arg Asn Tyr Pro Gin Val Asn Val Ile Asn Phe Thr 145 150 155 160 Thr Ser Trp Ser Asp Gly Leu Ala Leu Asn Ala Leu Ile His Ser His 165 170 175 Arg Pro Asp Leu Phe Asp Trp Asn Ser Val Val Cys Gin Gin Ser Ala 180 185 190 Thr Gin Arg Leu Glu His Ala Phe Asn Ile Ala Arg Tyr Gin Leu Gly

    2017200015 03 Jan 2017

    195 200 205 Ile Glu Lys Leu Leu Asp Pro Glu Asp Val Asp Thr Thr Tyr Pro Asp 210 215 220 Lys Lys Ser Ile Leu Met Tyr Ile Thr Ser Leu Phe Gin Val Leu Pro 225 230 235 240 Gin Gin Val Ser Ile Glu Ala Ile Gin Glu Val Glu Met Leu Pro Arg 245 250 255 Pro Pro Lys Val Thr Lys Glu Glu His Phe Gin Leu His His Gin Met 260 265 270 His Tyr Ser Gin Gin Ile Thr Val Ser Leu Ala Gin Gly Tyr Glu Arg 275 280 285 Thr Ser Ser Pro Lys Pro Arg Phe Lys Ser Tyr Ala Tyr Thr Gin Ala 290 295 300 Ala Tyr Val Thr Thr Ser Asp Pro Thr Arg Ser Pro Phe Pro Ser Gin 305 310 315 320 His Leu Glu Ala Pro Glu Asp Lys Ser Phe Gly Ser Ser Leu Met Glu 325 330 335 Ser Glu Val Asn Leu Asp Arg Tyr Gin Thr Ala Leu Glu Glu Val Leu 340 345 350 Ser Trp Leu Leu Ser Ala Glu Asp Thr Leu Gin Ala Gin Gly Glu Ile 355 360 365 Ser Asn Asp Val Glu Val Val Lys Asp Gin Phe His Thr His Glu Gly 370 375 380 Tyr Met Met Asp Leu Thr Ala His Gin Gly Arg Val Gly Asn Ile Leu 385 390 395 400 Gin Leu Gly Ser Lys Leu Ile Gly Thr Gly Lys Leu Ser Glu Asp Glu 405 410 415 Glu Thr Glu Val Gin Glu Gin Met Asn Leu Leu Asn Ser Arg Trp Glu 420 425 430 Cys Leu Arg Val Ala Ser Met Glu Lys Gin Ser Asn Leu His Arg Val 435 440 445 Leu Met Asp Leu Gin Asn Gin Lys Leu Lys Glu Leu Asn Asp Trp Leu 450 455 460 Thr Lys Thr Glu Glu Arg Thr Arg Lys Met Glu Glu Glu Pro Leu Gly 465 470 475 480 Pro Asp Leu Glu Asp Leu Lys Arg Gin Val Gin Gin His Lys Val Leu 485 490 495 Gin Glu Asp Leu Glu Gin Glu Gin Val Arg Val Asn Ser Leu Thr His 500 505 510 Met Val Val Val Val Asp Glu Ser Ser Gly Asp His Ala Thr Ala Ala 515 520 525 Leu Glu Glu Gin Leu Lys Val Leu Gly Asp Arg Trp Ala Asn Ile Cys 530 535 540 Arg Trp Thr Glu Asp Arg Trp Val Leu Leu Gin Asp Ile Leu Leu Lys 545 550 555 560

    2017200015 03 Jan 2017

    Trp Gin Arg Leu Thr 565 Glu Glu Gin Cys Leu 570 Phe Ser Ala Trp Leu 575 Ser Glu Lys Glu Asp Ala Val Asn Lys Ile His Thr Thr Gly Phe Lys Asp 580 585 590 Gin Asn Glu Met Leu Ser Ser Leu Gin Lys Leu Ala Val Leu Lys Ala 595 600 605 Asp Leu Glu Lys Lys Lys Gin Ser Met Gly Lys Leu Tyr Ser Leu Lys 610 615 620 Gin Asp Leu Leu Ser Thr Leu Lys Asn Lys Ser Val Thr Gin Lys Thr 625 630 635 640 Glu Ala Trp Leu Asp Asn Phe Ala Arg Cys Trp Asp Asn Leu Val Gin 645 650 655 Lys Leu Glu Lys Ser Thr Ala Gin Ile Ser Gin Ala Val Thr Thr Thr 660 665 670 Gin Pro Ser Leu Thr Gin Thr Thr Val Met Glu Thr Val Thr Thr Val 675 680 685 Thr Thr Arg Glu Gin Ile Leu Val Lys His Ala Gin Glu Glu Leu Pro 690 695 700 Pro Pro Pro Pro Gin Lys Lys Arg Gin Ile Thr Val Asp Thr Leu Glu 705 710 715 720 Arg Leu Gin Glu Leu Gin Glu Ala Thr Asp Glu Leu Asp Leu Lys Leu 725 730 735 Arg Gin Ala Glu Val Ile Lys Gly Ser Trp Gin Pro Val Gly Asp Leu 740 745 750 Leu Ile Asp Ser Leu Gin Asp His Leu Glu Lys Val Lys Ala Leu Arg 755 760 765 Gly Glu Ile Ala Pro Leu Lys Glu Asn Val Ser His Val Asn Asp Leu 770 775 780 Ala Arg Gin Leu Thr Thr Leu Gly Ile Gin Leu Ser Pro Tyr Asn Leu 785 790 795 800 Ser Thr Leu Glu Asp Leu Asn Thr Arg Trp Lys Leu Leu Gin Val Ala 805 810 815 Val Glu Asp Arg Val Arg Gin Leu His Glu Ala His Arg Asp Phe Gly 820 825 830 Pro Ala Ser Gin His Phe Leu Ser Thr Ser Val Gin Gly Pro Trp Glu 835 840 845 Arg Ala Ile Ser Pro Asn Lys Val Pro Tyr Tyr Ile Asn His Glu Thr 850 855 860 Gin Thr Thr Cys Trp Asp His Pro Lys Met Thr Glu Leu Tyr Gin Ser 865 870 875 880 Leu Ala Asp Leu Asn Asn Val Arg Phe Ser Ala Tyr Arg Thr Ala Met 885 890 895 Lys Leu Arg Arg Leu Gin Lys Ala Leu Cys Leu Asp Leu Leu Ser Leu 900 905 910 Ser Ala Ala Cys Asp Ala Leu Asp Gin His Asn Leu Lys Gin Asn Asp

    2017200015 03 Jan 2017

    915 920 925 Gin Pro 930 Met Asp Ile Leu Gin 935 Ile Ile Asn Cys Leu 940 Thr Thr Ile Tyr Asp Arg 945 Leu Glu Gin Glu His 950 Asn Asn Leu Val Asn 955 Val Pro Leu Cys 960 Val Asp Met Cys Leu Asn Trp 965 Leu Leu Asn Val Tyr 970 Asp Thr Gly Arg 975 Thr Gly Arg Ile Arg Val Leu 980 Ser Phe Lys Thr Gly 985 Ile Ile Ser Leu 990 Cys Lys Ala His Leu Glu Asp 995 Lys Tyr Arg Tyr Leu 1000 Phe Lys Gin Val 1005 Ala Ser Ser Thr Gly Phe Cys Asp Gin Arg Arg Leu Gly Leu Leu Leu 1010 1015 1020 His Asp 1025 Ser Ile Gin Ile Pro 1030 Arg Gin Leu Gly Glu 1035 Val Ala Ser Phe 1040 Gly Gly Ser Asn Ile Glu Pro 1045 Ser Val Arg Ser Cys 1050 Phe Gin Phe Ala 1055 Asn Asn Lys Pro Glu Ile Glu 1060 Ala Ala Leu Phe Leu 1065 Asp Trp Met Arg 1070 Leu Glu Pro Gin Ser Met Val 1075 Trp Leu Pro Val Leu 1080 His Arg Val Ala 1085 Ala Ala Glu Thr Ala Lys His Gin Ala Lys Cys Asn Ile Cys Lys Glu 1090 1095 1100 Cys Pro 1105 Ile Ile Gly Phe Arg 1110 Tyr Arg Ser Leu Lys 1115 His Phe Asn Tyr 1120 Asp Ile Cys Gin Ser Cys Phe 1125 Phe Ser Gly Arg Val 1130 Ala Lys Gly His 1135 Lys Met His Tyr Pro Met Val 1140 Glu Tyr Cys Thr Pro 1145 Thr Thr Ser Gly 1150 Glu Asp Val Arg Asp Phe Ala 1155 Lys Val Leu Lys Asn 1160 Lys Phe Arg Thr 1165 Lys Arg Tyr Phe Ala Lys His Pro Arg Met Gly Tyr Leu Pro Val Gin 1170 1175 1180 Thr Val Leu Glu Gly Asp Asn Met Glu Thr Asp Thr Met 1185 1190 1195

    <210> 4 <211> 1198 <212> PRT <213> Artificial Sequence <220>

    <223> canine MD1 <400> 4

    2017200015 03 Jan 2017

    Met Leu Trp Trp Glu Glu Val Glu Asp Cys Tyr Glu Arg Glu Asp Val 1 5 10 15 Gln Lys Lys Thr Phe Thr Lys Trp Ile Asn Ala Gln Phe Ser Lys Phe 20 25 30 Gly Lys Gln His Ile Glu Asn Leu Phe Ser Asp Leu Gln Asp Gly Arg 35 40 45 Arg Leu Leu Asp Leu Leu Glu Gly Leu Thr Gly Gln Lys Leu Pro Lys 50 55 60 Glu Lys Gly Ser Thr Arg Val His Ala Leu Asn Asn Val Asn Lys Ala 65 70 75 80 Leu Arg Val Leu Gln Lys Asn Asn Val Asp Leu Val Asp Ile Gly Ser 85 90 95 Thr Asp Ile Val Asp Gly Asn His Lys Leu Thr Leu Gly Leu Ile Trp 100 105 110 Asn Ile Ile Leu His Trp Gln Val Lys Asn Val Met Lys Asn Ile Met 115 120 125 Ala Gly Leu Gln Gln Thr Asn Ser Glu Lys Ile Leu Leu Ser Trp Val 130 135 140 Arg Gln Ser Thr Arg Asn Tyr Pro Gln Val Asn Val Ile Asn Phe Thr 145 150 155 160 Thr Ser Trp Ser Asp Gly Leu Ala Leu Asn Ala Leu Ile His Ser His 165 170 175 Arg Pro Asp Leu Phe Asp Trp Asn Ser Val Val Cys Gln Gln Ser Ala 180 185 190 Thr Gln Arg Leu Glu His Ala Phe Asn Ile Ala Lys Tyr Gln Leu Gly 195 200 205 Ile Glu Lys Leu Leu Asp Pro Glu Asp Val Ala Thr Thr Tyr Pro Asp 210 215 220 Lys Lys Ser Ile Leu Met Tyr Ile Thr Ser Leu Phe Gln Val Leu Pro 225 230 235 240 Gln Gln Val Ser Ile Glu Ala Ile Gln Glu Val Glu Met Leu Pro Arg 245 250 255 Pro Ser Lys Val Thr Arg Glu Glu His Phe Gln Leu His His Gln Met 260 265 270 His Tyr Ser Gln Gln Ile Thr Val Ser Leu Ala Gln Gly Tyr Glu Arg 275 280 285 Ala Pro Ser Ser Pro Lys Pro Arg Phe Lys Ser Tyr Ala Tyr Thr Gln 290 295 300 Ala Ala Tyr Val Thr Thr Ser Asp Pro Thr Arg Ser Pro Leu Pro Ser 305 310 315 320 Gln His Leu Glu Thr Pro Glu Asp Lys Ser Phe Gly Arg Ser Leu Thr 325 330 335 Glu Thr Glu Ala Asn Leu Asp Ser Tyr Gln Thr Ala Leu Glu Glu Val 340 345 350 Leu Ser Trp Leu Leu Ser Ala Glu Asp Ala Leu Gln Ala Gln Gly Glu

    2017200015 03 Jan 2017

    355 360 365 lie Ser Asn Asp Val Glu Glu Val Lys Glu Gin Phe His Thr His Glu 370 375 380 Gly Tyr Met Met Asp Leu Thr Ser His Gin Gly Arg Val Gly Asn Val 385 390 395 400 Leu Gin Leu Gly Ser Gin Leu lie Gly Thr Gly Lys Leu Ser Glu Asp 405 410 415 Glu Glu Thr Glu Val Gin Glu Gin Met Asn Leu Leu Asn Ser Arg Trp 420 425 430 Glu Cys Leu Arg Val Ala Ser Met Glu Lys Gin Ser Asn Leu His Lys 435 440 445 Val Leu Met Asp Leu Gin Asn Gin Gin Leu Lys Glu Leu Asn Asp Trp 450 455 460 Leu Thr Lys Thr Glu Glu Arg Thr Arg Lys Met Glu Lys Glu Pro Leu 465 470 475 480 Gly Pro Asp lie Glu Asp Leu Lys Arg Gin Val Gin Gin His Lys Val 485 490 495 Leu Gin Glu Asp Leu Glu Gin Glu Gin Val Arg Val Asn Ser Leu Thr 500 505 510 His Met Val Val Val Val Asp Glu Ser Ser Gly Asp His Ala Thr Ala 515 520 525 Ala Leu Glu Glu Gin Leu Lys Val Leu Gly Gly Arg Trp Ala Asn lie 530 535 540 Cys Arg Trp Thr Glu Asp Arg Trp Val Leu Leu Gin Asp lie Leu Leu 545 550 555 560 Lys Trp Gin Arg Phe Thr Glu Glu Gin Cys Leu Phe Ser Ala Trp Leu 565 570 575 Ser Glu Lys Glu Asp Ala Val Asn Lys lie His Thr Thr Gly Phe Lys 580 585 590 Asp Gin Ser Glu Val Leu Ser Asn Leu Gin Lys Leu Ala Val Leu Lys 595 600 605 Thr Asp Leu Glu Lys Lys Lys Gin Thr Met Asp Lys Leu Cys Ser Leu 610 615 620 Asn Gin Asp Leu Leu Ser Ala Leu Lys Asn Thr Val Val Ala His Lys 625 630 635 640 Met Glu Ala Trp Leu Asp Asn Ser Ala Gin Arg Trp Asp Asn Leu Val 645 650 655 Gin Lys Leu Glu Lys Ser Ser Ala Gin lie Ser Gin Ala Val Thr Thr 660 665 670 Thr Gin Pro Ser Leu Thr Gin Thr Thr Val Met Glu Thr Val Thr Met 675 680 685 Val Thr Thr Arg Glu His lie Leu Val Lys His Ala Gin Glu Glu Leu 690 695 700 Pro Pro Pro Pro Pro Gin Lys Lys Arg Gin lie lie Val Asp Ala Leu 705 710 715 720

    2017200015 03 Jan 2017

    Glu Arg Leu Gin Glu 725 Leu Gin Glu Ala Thr 730 Asp Glu Leu Asp Leu 735 Lys Leu Arg Gin Ala 740 Glu Val Ile Lys Gly 745 Ser Trp Gin Pro Val 750 Gly Asp Leu Leu Ile 755 Asp Ser Leu Gin Asp 760 His Leu Glu Lys Val Lys 765 Ala Leu Arg Gly Glu 770 Thr Thr Pro Leu 775 Lys Glu Asn Val Ser 780 Tyr Val Asn Asp Leu 785 Ala Arg Gin Leu Thr 790 Thr Leu Gly Ile Gin 795 Leu Ser Pro Tyr Asn 800 Leu Asn Thr Leu Glu 805 Asp Leu Asn Thr Arg 810 Trp Lys Leu Leu Gin 815 Val Ala Ile Glu Asp 820 Arg Ile Arg Gin Leu 825 His Glu Ala His Arg 830 Asp Phe Gly Pro Ala 835 Ser Gin His Phe Leu S40 Ser Thr Ser Val Gin Gly 845 Pro Trp Glu Arg Ala 850 Ile Ser Pro Asn 855 Lys Val Pro Tyr Tyr 860 Ile Asn His Glu Thr 865 Gin Thr Thr Cys Trp 870 Asp His Pro Lys Met 875 Thr Glu Leu Tyr Gin 880 Ser Leu Ala Asp Leu 885 Asn Asn Val Arg Phe 890 Ser Ala Tyr Arg Thr 895 Ala Met Lys Leu Arg 900 Arg Leu Gin Lys Ala 905 Leu Cys Leu Asp Leu 910 Leu Ser Leu Ser Ala 915 Ala Cys Asp Ala Leu 920 Asp Gin His Asn Leu Lys 925 Gin Asn Asp Gin Pro 930 Met Asp Ile Leu 935 Gin Val Ile Asn Cys 940 Leu Thr Thr Ile Tyr 945 Asp Arg Leu Glu Gin 950 Glu His Asn Asn Leu 955 Val Asn Val Pro Leu 960 Cys Val Asp Met Cys 965 Leu Asn Trp Leu Leu 970 Asn Val Tyr Asp Thr 975 Gly Arg Thr Gly Arg 980 Ile Arg Val Leu Ser 985 Phe Lys Thr Gly Ile 990 Ile Ser Leu Cys Lys 995 Ala His Leu Glu Asp Lys 1000 Tyr Arg Tyr Leu Phe 1005 Lys Gin Val Ala Ser 1010 Ser Thr Gly Phe Cys 1015 Asp Gin Arg Arg Leu Gly 1020 Leu Leu Leu His Asp 1025 Ser Ile Gin Ile 1030 Pro Arg Gin Leu Gly 1035 Glu Val Ala Ser 1040 Phe Gly Gly Ser Asn Ile 1045 Glu Pro Ser Val Arg 1050 Ser Cys Phe Gin Phe 1055 Ala Asn Asn Lys Pro 1060 Glu Ile Glu Ala Ala 1065 Leu Phe Leu Asp Trp 1070 Met Arg Leu Glu Pro Gin Ser Met Val Trp Leu Pro Val Leu His Arg Val

    2017200015 03 Jan 2017

    1075

    1080

    1085

    Ala Ala Ala Glu Thr Ala Lys His Gin Ala Lys Cys Asn Ile Cys Lys 1090 1095 1100 Glu Cys Pro Ile Ile Gly Phe Arg Tyr Arg Ser Leu Lys His Phe Asn 1105 1110 1115 1120 Tyr Asp Ile Cys Gin Ser Cys Phe Phe Ser Gly Arg Val Ala Lys Gly 1125 1130 1135 His Lys Met His Tyr Pro Met Val Glu Tyr Cys Thr Pro Thr Thr Ser 1140 1145 1150 Gly Glu Asp Val Arg Asp Phe Ala Lys Val Leu Lys Asn Lys Phe Arg 1155 1160 1165 Thr Lys Arg Tyr Phe Ala Lys His Pro Arg Met Gly Tyr Leu Pro Val 1170 1175 1180 Gin Thr Val Leu Glu Gly Asp Asn Met Glu Thr Asp Thr Met 1185 1190 1195

    <210> 5 <211> 3600 <212> DNA <213> Artificial Sequence <220>

    <223> opt human MD1 <400> 5 atgctgtggt gggaggaagt ggaggactgc tacgagagag aggacgtgca gaagaaaacc 60 ttcaccaagt gggtgaacgc ccagttcagc aagttcggca agcagcacat cgagaacctg 120 ttcagcgacc tgcaggatgg caggagactg ctggatctgc tggagggact gaccggccag 180 aagctgccca aggagaaggg cagcaccaga gtgcacgccc tgaacaacgt gaacaaggcc 240 ctgagagtgc tgcagaacaa caacgtggac ctggtgaata tcggcagcac cgacatcgtg 300 gacggcaacc acaagctgac cctgggcctg atctggaaca tcatcctgca ctggcaggtg 360 aagaacgtga tgaagaacat catggccggc ctgcagcaga ccaacagcga gaagatcctg 420

    2017200015 03 Jan 2017 ctgagctggg

    480 acctcctgga

    540 ttcgactgga

    600 aacatcgcca

    660 acctaccccg

    720 cagcaggtgt

    780 accaaggagg

    840 tccctggccc

    900 tacacccagg

    960 cacctggagg

    1020 ctggacagat

    1080 accctgcagg

    1140 acccacgagg

    1200 cagctgggca

    1260 caggagcaga

    1320 tgaggcagag gcgacggcct acagcgtggt gataccagct acaagaaaag ccatcgaggc agcacttcca agggctatga ccgcctacgt cccccgagga accagaccgc cccagggcga gctacatgat gcaagctgat tgaacctgct caccagaaac ggccctgaac gtgtcagcag gggcatcgag catcctgatg catccaggaa gctgcaccac gagaaccagc gaccacctcc caagagcttc cctggaggaa gatcagcaac ggatctgacc cggcaccggc gaacagcaga tacccccagg gccctgatcc agcgccaccc aagctgctgg tatattacct gtggaaatgc cagatgcact agccccaagc gaccccacca ggcagcagcc gtgctgtctt gacgtggaag gcccaccagg aagctgagcg tgggagtgcc tgaacgtgat acagccacag agagactgga accccgagga ctctgtttca tgcccaggcc atagccagca ccagattcaa gaagcccctt tgatggagag ggctgctgtc tggtgaagga gcagagtggg aggacgagga tgagagtggc caacttcacc acccgacctg gcacgccttc cgtggacacc ggtgctgccc ccccaaagtg gatcaccgtg gagctacgcc ccccagccag cgaagtgaac cgccgaggac ccagttccac caatatcctg gaccgaagtg cagcatggag

    2017200015 03 Jan 2017 aagcagagca

    1380 aacgactggc

    1440 cccgacctgg

    1500 gaacaggagc

    1560 agcggcgacc

    1620 gccaacatct

    1680 tggcagagac

    1740 gccgtgaaca

    1800 cagaagctgg

    1860 tactccctga

    1920 gaggcctggc

    1980 agcaccgccc

    2040 gtgatggaga

    2100 gaggagctgc

    2160 agactgcagg

    2220 acctgcaccg tgaccaagac aggacctgaa aggtgcgcgt acgccacagc gccggtggac tgacagagga agatccacac ccgtgctgaa agcaggacct tggacaattt agatcagcca ccgtgaccac cccctccccc agctgcagga cgtgctgatg cgaggagcgg gagacaggtg gaacagcctg cgccctggaa cgaggacaga gcagtgcctg caccggcttc ggccgatctg gctgtccacc cgcccggtgc ggccgtgacc agtgaccacc ccctcagaag agccaccgac gacctgcaga accagaaaga cagcagcaca acccacatgg gagcagctga tgggtgctgc tttagcgcct aaggaccaga gagaagaaaa ctgaagaaca tgggacaatc accacccagc agggagcaga aagcggcaga gagctggacc accagaagct tggaggagga aagtgctgca tggtcgtggt aagtgctggg tgcaggacat ggctgagcga acgagatgct agcagagcat agagcgtgac tggtgcagaa ccagcctgac tcctggtgaa tcacagtgga tgaagctgag gaaggagctg gcccctgggc ggaggacctg ggacgagagc cgacagatgg cctgctgaag gaaggaggac gagcagcctg gggcaagctg ccagaaaacc actggagaag acagaccacc gcacgcccag caccctggag acaggccgaa

    2017200015 03 Jan 2017 gtgatcaagg

    2280 ctggagaaag

    2340 gtgaacgacc

    2400 agcaccctgg

    2460 gtgaggcagc

    2520 accagcgtgc

    2580 aaccacgaga

    2640 ctggccgacc

    2700 ctgcagaagg

    2760 cagcacaacc

    2820 accaccatct

    2880 gtggacatgt

    2940 agagtgctgt

    3000 taccgctacc

    3060 ggcctgctgc

    3120 gcagctggca tgaaggccct tggccagaca aagatctgaa tgcacgaggc agggcccctg cccagaccac tgaacaatgt ccctgtgcct tgaagcagaa acgatcggct gcctgaattg ccttcaagac tgttcaagca tgcacgatag gcctgtgggc gcggggcgag gctgaccacc cacccggtgg ccacagagac ggagagagcc ctgctgggac gcggttcagc ggacctgctg cgaccagccc ggagcaggag gctgctgaac cggcatcatc ggtggccagc catccagatc gatctgctga atcgcccccc ctgggcatcc aaactgctgc ttcggccctg atctccccca caccctaaga gcctacagaa agcctgagcg atggacattc cacaacaacc gtgtacgaca agcctgtgca agcaccggct cctaggcagc tcgacagcct tgaaggagaa agctgagccc aggtggccgt cctcccagca acaaagtgcc tgaccgagct ccgccatgaa ccgcctgcga tgcagatcat tggtgaacgt ccggcaggac aggcccacct tctgcgatca tgggcgaagt gcaggaccac tgtgagccac ctacaatctg ggaggataga cttcctgagc ctactacatc gtaccagagc gctgcggaga cgccctggac caactgcctg gcccctgtgc cggcagaatc ggaggataag gaggagactg ggccagcttt

    2017200015 03 Jan 2017 ggcggcagca acatcgagcc ctctgtgagg agctgcttcc agttcgccaa 3180 gagatcgagg ccgccctgtt cctggattgg atgaggctgg agccccagag 3240 ctgcctgtgc tgcacagagt ggccgccgcc gagaccgcca agcaccaggc 3300 atctgcaagg agtgccccat catcggcttc cggtacagga gcctgaagca 3360 gacatctgcc agagctgctt tttcagcggc agagtggcca agggccacaa 3420 cccatggtgg agtactgcac ccccaccacc tccggcgagg atgtgagaga 3480 gtgctgaaga ataagttccg gaccaagcgg tactttgcca agcaccccag 3540 ctgcccgtgc agaccgtgct ggagggcgac aacatggaga ccgacaccat 3600 caacaagccc catggtgtgg caagtgcaac cttcaactac gatgcactac cttcgccaaa gatgggctac gtgatgatga <210> 6 <211> 3603 <212> DNA <213> Artificial Sequence <220>

    <223> opt canine MD1 <400> 6 atgctgtggt gggaggaagt ggaggactgc tacgagagag aggacgtgca 60 ttcaccaagt ggatcaacgc ccagttcagc aagttcggca agcagcacat 120 ttcagcgatc tgcaggatgg caggagactg ctggatctgc tggagggact 180 aagctgccca aggagaaggg cagcaccaga gtgcacgccc tgaacaacgt 240 gaagaaaacc cgagaacctg gaccggccag gaacaaggcc

    2017200015 03 Jan 2017 ctgagagtgc

    300 gacggcaacc

    360 aagaacgtga

    420 ctgagctggg

    480 acctcctgga

    540 ttcgactgga

    600 aacatcgcca

    660 acctaccccg

    720 cagcaggtgt

    780 accagggagg

    840 tccctggccc

    900 gcctacaccc

    960 cagcacctgg

    1020 aacctggata

    1080 gacgccctgc

    1140 tgcagaagaa acaagctgac tgaagaacat tgaggcagag gcgacggcct acagcgtggt agtaccagct acaagaaaag ccatcgaggc agcacttcca agggctatga aggccgccta agacccctga gctaccagac aggcccaggg caacgtggac cctgggcctg catggccggc caccagaaac ggccctgaac gtgtcagcag gggcatcgag catcctgatg catccaggaa gctgcaccac gagagcccct cgtgaccacc ggataagagc cgccctggag cgagatcagc ctggtggata atctggaaca ctgcagcaga tacccccagg gccctgatcc agcgccaccc aagctgctgg tatattacca gtggaaatgc cagatgcact agcagcccca tccgacccca ttcggcagaa gaagtgctgt aacgacgtgg tcggcagcac tcatcctgca ccaacagcga tgaacgtgat acagccacag agagactgga accccgagga gcctgttcca tgcccaggcc atagccagca agccccggtt ccagaagccc gcctgaccga cttggctgct aagaagtgaa cgacatcgtg ctggcaggtg gaagatcctg caacttcacc acccgacctg gcacgccttc cgtggccacc ggtgctgccc cagcaaagtg gatcaccgtg caagagctac cctgcccagc gaccgaggcc gtccgccgag ggagcagttc

    2017200015 03 Jan 2017 cacacccacg

    1200 ctgcagctgg

    1260 gtgcaggaac

    1320 gagaagcaga

    1380 ctgaacgact

    1440 ggccctgaca

    1500 ctggagcagg

    1560 agcagcggcg

    1620 tgggccaata

    1680 aagtggcaga

    1740 gacgccgtga

    1800 ctgcagaagc

    1860 ctgtgcagcc

    1920 atggaggcct

    1980 aagagcagcg

    2040 agggctacat gcagccagct agatgaacct gcaacctgca ggctgaccaa tcgaggacct agcaggtgcg accacgccac tctgccggtg gattcaccga acaagatcca tggccgtgct tgaaccagga ggctggataa cccagatcag gatggacctg gatcggcacc gctgaacagc caaagtgctg gacagaggag gaagaggcag cgtgaacagc agccgccctg gaccgaggac ggagcagtgc caccaccggc gaaaaccgac cctgctgagc tagcgctcag ccaggccgtg accagccacc ggcaagctga agatgggagt atggatctgc cggacccgga gtgcagcagc ctgacccaca gaagagcagc agatgggtgc ctgtttagcg ttcaaggacc ctggagaaga gccctgaaga agatgggata accaccaccc agggcagagt gcgaggacga gcctgagagt agaaccagca agatggagaa ataaggtcct tggtggtcgt tgaaagtgct tgctgcagga cctggctgag agagcgaagt aaaagcagac acaccgtggt atctggtgca agcccagcct gggcaacgtg ggagaccgaa ggccagcatg gctgaaggag ggagcccctg gcaggaggat ggtggacgag gggcggcaga catcctgctg cgagaaggag gctgtccaac catggacaag ggcccacaag gaaactggag gacacagacc

    2017200015 03 Jan 2017 accgtgatgg

    2100 caggaggagc

    2160 gagagactgc

    2220 gaagtgatca

    2280 cacctggaga

    2340 tacgtgaacg

    2400 ctgaacaccc

    2460 cggatcaggc

    2520 agcaccagcg

    2580 atcaaccacg

    2640 agcctggccg

    2700 agactgcaga

    2760 gaccagcaca

    2820 ctgaccacca

    2880 tgcgtggaca

    2940 agaccgtgac tgccccctcc aggagctgca agggcagctg aagtgaaggc acctggccag tggaggatct agctgcacga tgcagggccc agacccagac acctgaacaa aggccctgtg acctgaagca tctacgatcg tgtgcctgaa catggtgacc cccccctcag ggaagccacc gcagcctgtg cctgcggggc acagctgacc gaacacccgg ggcccacaga ctgggagaga cacctgctgg tgtgcggttc cctggacctg gaacgaccag gctggagcag ttggctgctg accagggagc aagaagcggc gacgagctgg ggcgatctgc gagaccaccc accctgggca tggaaactgc gacttcggcc gccatcagcc gaccacccta agcgcctaca ctgtccctga cccatggata gagcacaaca aacgtgtacg acatcctggt agatcatcgt acctgaagct tgatcgacag ccctgaagga ttcagctgag tgcaggtggc ctgcttctca ccaacaaagt agatgaccga gaaccgccat gcgccgcctg tcctgcaggt acctggtgaa acaccggcag gaagcacgcc ggatgccctg gagacaggcc cctgcaggac gaacgtgtcc cccctacaac cattgaggac gcatttcctg gccctactac gctgtaccag gaagctgcgg cgacgccctg gatcaactgc cgtgcccctg gaccggcaga

    2017200015 03 Jan 2017 atcagagtgc tgtccttcaa gaccggcatc atcagcctgt gcaaggccca 3000 aagtaccgct acctgttcaa gcaggtggcc agcagcaccg gcttctgcga 3060 ctgggcctgc tgctgcacga tagcatccag atccctaggc agctgggcga 3120 tttggcggca gcaacatcga gccctctgtg aggagctgct tccagttcgc 3180 cccgagatcg aggccgccct gttcctggat tggatgaggc tggagcccca 3240 tggctgcctg tgctgcacag agtggccgcc gccgagaccg ccaagcacca 3300 aacatctgca aggagtgccc catcatcggc ttccggtaca ggagcctgaa 3360 tacgacatct gccagagctg ctttttcagc ggcagagtgg ccaagggcca 3420 taccccatgg tggagtactg cacccccacc acctccggcg aggatgtgag 3480 aaagtgctga agaataagtt ccggaccaag cggtactttg ccaagcaccc 3540 tacctgcccg tgcagaccgt gctggagggc gacaacatgg agaccgacac 3600 t g

    3603 cctggaggat tcagaggaga agtggccagc caacaacaag gagcatggtg ggccaagtgc gcacttcaac caagatgcac agacttcgcc caggatgggc catgtgatga <210> 7 <211> 1199 <212> PRT <213> Artificial Sequence <220>

    <223> murine MD1

    2017200015 03 Jan 2017

    <400> 7 Met Leu Trp Trp Glu Glu Val Glu Asp Cys Tyr Glu Arg Glu Asp Val 1 5 10 15 Gin Lys Lys Thr Phe Thr Lys Trp Ile Asn Ala Gin Phe Ser Lys Phe 20 25 30 Gly Lys Gin His Ile Asp Asn Leu Phe Ser Asp Leu Gin Asp Gly Lys 35 40 45 Arg Leu Leu Asp Leu Leu Glu Gly Leu Thr Gly Gin Lys Leu Pro Lys 50 55 60 Glu Lys Gly Ser Thr Arg Val His Ala Leu Asn Asn Val Asn Lys Ala 65 70 75 80 Leu Arg Val Leu Gin Lys Asn Asn Val Asp Leu Val Asn Ile Gly Ser 85 90 95 Thr Asp Ile Val Asp Gly Asn His Lys Leu Thr Leu Gly Leu Ile Trp 100 105 110 Asn Ile Ile Leu His Trp Gin Val Lys Asn Val Met Lys Thr Ile Met 115 120 125 Ala Gly Leu Gin Gin Thr Asn Ser Glu Lys Ile Leu Leu Ser Trp Val 130 135 140 Arg Gin Ser Thr Arg Asn Tyr Pro Gin Val Asn Val Ile Asn Phe Thr 145 150 155 160 Ser Ser Trp Ser Asp Gly Leu Ala Leu Asn Ala Leu Ile His Ser His 165 170 175 Arg Pro Asp Leu Phe Asp Trp Asn Ser Val Val Ser Gin His Ser Ala 180 185 190 Thr Gin Arg Leu Glu His Ala Phe Asn Ile Ala Lys Cys Gin Leu Gly 195 200 205 Ile Glu Lys Leu Leu Asp Pro Glu Asp Val Ala Thr Thr Tyr Pro Asp 210 215 220 Lys Lys Ser Ile Leu Met Tyr Ile Thr Ser Leu Phe Gin Val Leu Pro 225 230 235 240 Gin Gin Val Ser Ile Glu Ala Ile Gin Glu Val Glu Met Leu Pro Arg 245 250 255 Thr Ser Ser Lys Val Thr Arg Glu Glu His Phe Gin Leu His His Gin 260 265 270 Met His Tyr Ser Gin Gin Ile Thr Val Ser Leu Ala Gin Gly Tyr Glu 275 280 285 Gin Thr Ser Ser Ser Pro Lys Pro Arg Phe Lys Ser Tyr Ala Phe Thr 290 295 300 Gin Ala Ala Tyr Val Ala Thr Ser Asp Ser Thr Gin Ser Pro Tyr Pro 305 310 315 320 Ser Gin His Leu Glu Ala Pro Arg Asp Lys Ser Leu Asp Ser Ser Leu 325 330 335 Met Glu Thr Glu Val Asn Leu Asp Ser Tyr Gin Thr Ala Leu Glu Glu

    2017200015 03 Jan 2017

    340 345 350 Val Leu Ser Trp Leu Leu Ser Ala Glu Asp Thr Leu Arg Ala Gin Gly 355 360 365 Glu Ile Ser Asn Asp Val Glu Glu Val Lys Glu Gin Phe His Ala His 370 375 380 Glu Gly Phe Met Met Asp Leu Thr Ser His Gin Gly Leu Val Gly Asn 385 390 395 400 Val Leu Gin Leu Gly Ser Gin Leu Val Gly Lys Gly Lys Leu Ser Glu 405 410 415 Asp Glu Glu Ala Glu Val Gin Glu Gin Met Asn Leu Leu Asn Ser Arg 420 425 430 Trp Glu Cys Leu Arg Val Ala Ser Met Glu Lys Gin Ser Lys Leu His 435 440 445 Lys Val Leu Met Asp Leu Gin Asn Gin Lys Leu Lys Glu Leu Asp Asp 450 455 460 Trp Leu Thr Lys Thr Glu Glu Arg Thr Lys Lys Met Glu Glu Glu Pro 465 470 475 480 Phe Gly Pro Asp Leu Glu Asp Leu Lys Cys Gin Val Gin Gin His Lys 485 490 495 Val Leu Gin Glu Asp Leu Glu Gin Glu Gin Val Arg Val Asn Ser Leu 500 505 510 Thr His Met Val Val Val Val Asp Glu Ser Ser Gly Asp His Ala Thr 515 520 525 Ala Ala Leu Glu Glu Gin Leu Lys Val Leu Gly Asp Arg Trp Ala Asn 530 535 540 Ile Cys Arg Trp Thr Glu Asp Arg Trp Ile Val Leu Gin Asp Ile Leu 545 550 555 560 Leu Lys Trp Gin His Phe Thr Glu Glu Gin Cys Leu Phe Ser Thr Trp 565 570 575 Leu Ser Glu Lys Glu Asp Ala Met Lys Asn Ile Gin Thr Ser Gly Phe 580 585 590 Lys Asp Gin Asn Glu Met Met Ser Ser Leu His Lys Ile Ser Thr Leu 595 600 605 Lys Ile Asp Leu Glu Lys Lys Lys Pro Thr Met Glu Lys Leu Ser Ser 610 615 620 Leu Asn Gin Asp Leu Leu Ser Ala Leu Lys Asn Lys Ser Val Thr Gin 625 630 635 640 Lys Met Glu Ile Trp Met Glu Asn Phe Ala Gin Arg Trp Asp Asn Leu 645 650 655 Thr Gin Lys Leu Glu Lys Ser Ser Ala Gin Ile Ser Gin Ala Val Thr 660 665 670 Thr Thr Gin Pro Ser Leu Thr Gin Thr Thr Val Met Glu Thr Val Thr 675 680 685 Met Val Thr Thr Arg Glu Gin Ile Met Val Lys His Ala Gin Glu Glu 690 695 700

    2017200015 03 Jan 2017

    Leu Pro Pro Pro Pro Pro Gin Lys Lys Arg Gin Ile Thr Val Asp Ala 705 710 715 720 Leu Glu Arg Leu Gin Glu Leu Gin Glu Ala Ala Asp Glu Leu Asp Leu 725 730 735 Lys Leu Arg Gin Ala Glu Val Ile Lys Gly Ser Trp Gin Pro Val Gly 740 745 750 Asp Leu Leu Ile Asp Ser Leu Gin Asp His Leu Glu Lys Val Lys Ala 755 760 765 Leu Arg Gly Glu Ile Ala Pro Leu Lys Glu Asn Val Asn Arg Val Asn 770 775 780 Asp Leu Ala His Gin Leu Thr Thr Leu Gly Ile Gin Leu Ser Pro Tyr 785 790 795 800 Asn Leu Ser Thr Leu Glu Asp Leu Asn Thr Arg Trp Arg Leu Leu Gin 805 810 815 Val Ala Val Glu Asp Arg Val Arg Gin Leu His Glu Ala His Arg Asp 820 825 830 Phe Gly Pro Ala Ser Gin His Phe Leu Ser Thr Ser Val Gin Gly Pro 835 840 845 Trp Glu Arg Ala Ile Ser Pro Asn Lys Val Pro Tyr Tyr Ile Asn His 850 855 860 Glu Thr Gin Thr Thr Cys Trp Asp His Pro Lys Met Thr Glu Leu Tyr 865 870 875 880 Gin Ser Leu Ala Asp Leu Asn Asn Val Arg Phe Ser Ala Tyr Arg Thr 885 890 895 Ala Met Lys Leu Arg Arg Leu Gin Lys Ala Leu Cys Leu Asp Leu Leu 900 905 910 Ser Leu Ser Ala Ala Cys Asp Ala Leu Asp Gin His Asn Leu Lys Gin 915 920 925 Asn Asp Gin Pro Met Asp Ile Leu Gin Ile Ile Asn Cys Leu Thr Thr 930 935 940 Ile Tyr Asp Arg Leu Glu Gin Glu His Asn Asn Leu Val Asn Val Pro 945 950 955 960 Leu Cys Val Asp Met Cys Leu Asn Trp Leu Leu Asn Val Tyr Asp Thr 965 970 975 Gly Arg Thr Gly Arg Ile Arg Val Leu Ser Phe Lys Thr Gly Ile Ile 980 985 990 Ser Leu Cys Lys Ala His Leu Glu Asp Lys Tyr Arg Tyr Leu Phe Lys 995 1000 1005 Gin Val Ala Ser Ser Thr Gly Phe Cys Asp Gin Arg Arg Leu Gly Leu 1010 1015 1020 Leu Leu His Asp Ser Ile Gin Ile Pro Arg Gin Leu Gly Glu Val Ala 1025 1030 1035 1040 Ser Phe Gly Gly Ser Asn Ile Glu Pro Ser Val Arg Ser Cys Phe Gin 1045 1050 1055 Phe Ala Asn Asn Lys Pro Glu Ile Glu Ala Ala Leu Phe Leu Asp Trp

    2017200015 03 Jan 2017

    1060 1065 1070

    Met Arg Leu Glu Pro Gin Ser Met Val 1080 Trp Leu Pro Val Leu His 1085 Arg 1075 Val Ala Ala Ala Glu Thr Ala Lys His Gin Ala Lys Cys Asn lie Cys 1090 1095 1100 Lys Glu Cys Pro lie lie Gly Phe Arg Tyr Arg Ser Leu Lys His Phe 1105 1110 1115 1120 Asn Tyr Asp lie Cys Gin Ser Cys Phe Phe Ser Gly Arg Val Ala Lys 1125 1130 1135 Gly His Lys Met His Tyr Pro Met Val Glu Tyr Cys Thr Pro Thr Thr 1140 1145 1150 Ser Gly Glu Asp Val Arg Asp Phe Ala Lys Val Leu Lys Asn Lys Phe 1155 1160 1165 Arg Thr Lys Arg Tyr Phe Ala Lys His Pro Arg Met Gly Tyr Leu Pro 1170 1175 1180 Val Gin Thr Val Leu Glu Gly Asp Asn Met Glu Thr Asp Thr Met 1185 1190 1195

    <210> 8 <211> 3611 <212> DNA <213> Artificial Sequence <220>

    <223> opt murine MD1 <400> 8

    atgctgtggt 60 gggaggaagt ggaggactgc tacgagagag aggacgtgca gaagaaaacc ttcaccaagt 120 ggatcaacgc ccagttcagc aagttcggca agcagcacat cgacaacctg ttcagcgacc 180 tgcaggacgg caagagactg ctggatctgc tggagggact gaccggccag aagctgccca 240 aggagaaggg cagcaccaga gtgcacgccc tgaacaacgt gaacaaggcc ctgagagtgc 300 tgcagaagaa caacgtggac ctggtgaata tcggcagcac cgacatcgtg gacggcaacc 360 acaagctgac cctgggcctg atctggaaca tcatcctgca ctggcaggtg

    2017200015 03 Jan 2017 aagaacgtga

    420 ctgagctggg

    480 agcagctgga

    540 ttcgactgga

    600 aacatcgcca

    660 acctaccccg

    720 cagcaggtgt

    780 gtgacccggg

    840 gtgtccctgg

    900 tacgccttca

    960 agccagcacc

    1020 gtgaacctgg

    1080 gaggacaccc

    1140 ttccacgccc

    1200 gtgctgcagc

    1260 tgaaaaccat tgaggcagag gcgacggcct acagcgtggt agtgccagct acaagaaaag ccatcgaggc aggagcactt cccagggcta cccaggccgc tggaggcccc acagctacca tgagagccca acgagggctt tgggcagcca catggccggc caccagaaac ggccctgaac gtcccagcac gggcatcgag catcctcatg catccaggaa ccagctgcac cgagcagacc ctacgtggcc tagagacaag gaccgccctg gggcgagatc catgatggac gctcgtggga ctgcagcaga tacccccagg gccctgatcc agcgccaccc aagctgctgg tatatcacct gtggaaatgc caccagatgc agcagctccc acaagcgata agcctggaca gaggaagtgc agcaacgacg ctgacctccc aagggcaagc ccaacagcga tgaacgtgat acagccacag agagactgga accccgagga ctctgtttca tgccccggac actatagcca ccaagcccag gcacccagag gcagcctgat tgtcttggct tggaagaagt atcagggcct tgagcgagga gaagatcctg caacttcacc acccgacctg gcacgccttc cgtggccacc ggtgctgccc cagcagcaaa gcagatcacc attcaagagc cccctacccc ggagacagaa gctgtccgcc gaaggagcag ggtgggcaac cgaggaggcc

    2017200015 03 Jan 2017 gaagtgcagg

    1320 atggagaagc

    1380 gaactggacg

    1440 ttcggccccg

    1500 gacctggaac

    1560 gagagcagcg

    1620 agatgggcca

    1680 ctgaagtggc

    1740 gaggacgcca

    1800 agcctgcaca

    1860 aagctgtcca

    1920 aaaatggaga

    1980 gagaagagca

    2040 accaccgtga

    2100 gcccaggagg

    2160 aacagatgaa agagcaagct actggctgac acctggagga aggagcaggt gcgaccacgc atatctgccg agcacttcac tgaagaacat agatcagcac gcctgaacca tctggatgga gcgcccagat tggagaccgt agctgccccc cctgctgaac gcacaaagtg caagaccgag cctgaagtgc gcgcgtgaac cacagccgcc gtggaccgag cgaggagcag ccagaccagc cctgaagatc ggacctgctg gaatttcgca cagccaggcc gaccatggtg tcccccccct agcagatggg ctgatggatc gagcggacca caggtgcagc agcctgaccc ctggaagagc gatagatgga tgcctgttta ggcttcaagg gacctggaga agcgccctga cagaggtggg gtgaccacca accacccggg cagaagaagc agtgcctgag tgcagaacca agaagatgga agcataaggt acatggtggt agctgaaagt tcgtgctgca gcacctggct accagaacga agaaaaagcc agaacaagag acaacctgac cccagcccag agcagatcat ggcagatcac agtggccagc gaagctgaag ggaggagccc cctgcaggag cgtggtggac gctgggcgac ggacatcctg gagcgagaaa gatgatgagc cacaatggag cgtgacccag ccagaagctg cctgacacag ggtgaagcac agtggatgcc

    2017200015 03 Jan 2017 ctggagagac

    2220 gccgaagtga

    2280 gaccacctgg

    2340 aaccgcgtga

    2400 aacctgagca

    2460 gatagagtga

    2520 ctgagcacca

    2580 tacatcaacc

    2640 cagagcctgg

    2700 cggagactgc

    2760 ctggaccagc

    2820 tgcctgacca

    2880 ctgtgcgtgg

    2940 agaatcagag

    3000 gataagtacc

    3060 tgcaggagct tcaagggcag agaaagtgaa acgacctggc ccctggagga ggcagctgca gcgtgcaggg acgagaccca ccgacctgaa agaaggccct acaacctgaa ccatctacga acatgtgcct tgctgtcctt gctacctgtt gcaggaagcc ctggcagcct ggccctgcgg ccatcagctg tctgaacacc cgaggcccac cccctgggag gaccacctgc caatgtgcgg gtgcctggac gcagaacgac tcggctggag gaattggctg caagaccggc caagcaggtg gccgacgagc gtgggcgatc ggcgagatcg accaccctgg cggtggagac agagacttcg agagccatca tgggaccacc ttcagcgcct ctgctgtccc cagcccatgg caggagcaca ctgaacgtgt atcatcagcc gccagcagca tggatctgaa tgctgatcga cccccctgaa gcattcagct tgctgcaggt gccctgcctc gccccaacaa ctaagatgac acagaaccgc tgagcgccgc atatcctgca acaacctggt acgacaccgg tgtgcaaggc ccggcttctg gctgagacag cagcctgcag ggagaacgtg gagcccctac ggccgtggag ccagcacttc agtgccctac cgagctgtac catgaagctg ctgcgacgcc gatcatcaac gaacgtgccc caggaccggc ccacctggag cgatcagagg

    2017200015 03 Jan 2017 agactgggcc tgctgctgca cgatagcatc cagatcccta ggcagctggg 3120 agctttggcg gcagcaacat cgagccctct gtgaggagct gcttccagtt 3180 aagcccgaga tcgaggccgc cctgttcctg gattggatga ggctggagcc 3240 gtgtggctgc ctgtgctgca cagagtggcc gccgccgaga ccgccaagca 3300 tgcaacatct gcaaggagtg ccccatcatc ggcttccggt acaggagcct 3360 aactacgaca tctgccagag ctgctttttc agcggcagag tggccaaggg 3420 cactacccca tggtggagta ctgcaccccc accacctccg gcgaggatgt 3480 gccaaagtgc tgaagaataa gttccggacc aagcggtact ttgccaagca 3540 ggctacctgc ccgtgcagac cgtgctggag ggcgacaaca tggagaccga 3600 tgtgatgatg

    3611 cgaagtggcc cgccaacaac ccagagcatg ccaggccaag gaagcacttc ccacaagatg gagagacttc ccccaggatg caccatgtga